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Abstract: 
Atopic dermatitis (AD) is a chronic, distressing disease, affecting up to 20% of 
Hong Kong child population. It is associated with pruritus and sleep disturbance. The 
sensation of pruritus involves a complex neuro-signaling pathway. Scratching due to 
itching is an important mechanism in the pathogenesis of AD but is difficult to be 
documented. Subjective symptoms of pruritus and sleep loss reported by parents 
correlated only weakly with the objective signs (extent and intensity) of AD severity, 
whereas traditional objective assessments are inconvenient and cannot be carried out 
in a home-based environment. 
A new wristwatch-alike motionlogger has therefore been adopted as a trial for 
home-based convenient assessment of itch. Forty-three Chinese children with AD 
(mean [SD] age of 11.9 [3.6] years) and thirty-seven normal children, aged 11.9 (3.4) 
years were recruited for device validation. 2 clinical trials of traditional Chinese 
herbal medication and Tacrolimus calcineurin inhibitor were also conducted. AD 
disease severities of the subjects were firstly evaluated with the SCORing Atopic 
Dermatitis (SCORAD) index. Subjective reports of pruritus, sleep loss and a 
questionnaire of Children's Dermatology Life Quality Index (CDLQI) were 
performed. Concentrations of plasma AD-associated chemokines (cutaneous T cell 
attracting cytokine, CTACK; thymus and activation regulated chemokine, TARC) and 
v i i 
pruritus-causing laboratory markers (Brain-derived neurotrophic factor，BDNF and 
substance-P) were measured in patients. Patients were then instructed to wear 
Digitrac® movement recorder (IM Systems, Baltimore, MD) on their dominant wrist 
before sleeping. The monitor had been programmed to start logging limb motion 
continuously from 22:00 to 08:00 h the next morning. The contour pattern between 
eczema patients and controls were compared to see if any unique patterns could be 
distinguished. 
When visually compared with controls, most wrist activities occurred at 
frequencies from 0 to 3 hertz. These activities were most consistent over the first three 
hours of sleeping and significantly correlated with disease extent, intensity，plasma 
AD-associated chemokines and pruritic markers. However, there was no significant 
correlation between wrist activities and subjective scorings. Wrist activity 
measurement by such a device is therefore useful in obtaining the pruritus and 
sleeping data of patients conveniently in an objective manner, and leaves a large room 
for applying to determine drug efficacies of various AD medications and other 
diseases associated with pruritus. 
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論文槪要： 
異位性皮膚炎是一種慢性及困擾的病症。全港大約有約百分之二十的兒童正 
受到該症困擾，而該病症往往與痕癢和睡眠干擾聯繁在一起。人體對痕癢的感覺 
牽涉一個很複雜的神經信號網絡，而抓癢雖然是一種異位性皮膚炎的重要病發原 
理機制’但很難被證明。另一方面，病人對痕癢及睡眠影響的主觀匯報與客觀的 
疾病程度、強度標示只有微弱的關聯，而同時傳統的客觀評估方法十分不方便， 
並不能在家中環境進行。 
因此，一個薪新的手部運動紀錄儀被正式用在是次測試中，以在家中環境作 
客觀評估痕癢程度之用。四十三名患有異位性皮膚炎病童及三十七名對照參加者 
被邀請作是次儀器檢驗之用，另外兩個中草藥及Tacrolimus躬調神經碟酸酶抑制 
劑之臨床測試亦有進行。病童的病症嚴重程度以異位性皮膚炎評分指標 
(SCORAD)作評估，而病人對痕癢及睡眠狀況的主觀報告及兒童皮膚科生活質素 
指數問卷亦同時進行。病童血壞內與異位性皮膚炎有關聯之胸腺和活化調節趨化 
因子(TARC)�皮膚T细胞吸引趨化因子(CTACK)，及與痕癢有關聯之腦衍生神 
經滋養因子(BDNF)和P物資(SP)之濃度亦被量度作硏究用。病童會按指示在睡 
眠前配戴Digitrac®手部運動紀錄儀在主手腕上，該儀器被設定連續記錄由晚上十 
時至翌日早上八時的手部活動情況。病童與對照參加者的活動分佈輪_會作比 
較，藉以觀察有否特別活動模式。 
當通過程式與對照比較，病童多數手腕活動發生頻率位於0到3赫兹內， 
ix 
而這些活動在頭三小時的睡眠是最一致的，並與疾病程度、強度、血漿內與濕疼 
有關之趨化因子及痕癢指標有顯著關聯。不過，手腕活動與主觀評分沒有顯著關 
聯。因此，利用該儀器能有效並客觀地獲取病人的痕癢和睡眠數據，並在應用於 
評估濕疼治療藥物功效及其他與痕癢有關聯之病症存在很大空間。 
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Chapter 1 
Introduction and Literature Review 
1.1 General aspects of atopic dermatitis 
1.1.1 Definition and its nature 
Atopic dermatitis (AD) (or atopic eczema) is one of the most common chronic 
inflammatory skin disorders occurring in infants and children. The term 'atopy' was first 
being used by two allergists, Coco and Cooke, and the term 'atopic dermatitis' was 
originated in 1933 in order to distinguish it from other dermatologic disorders (Figure 1.1) 
(Coco and Cooke, 1923;Williams et al, 1994). Atopy has been defined by the European 
Academy of Allergy and Clinical Immunology (EAACI) Nomenclature Task Force as "a 
personal tendency, familial tendency, or both, usually in childhood and adolescence, to 
become sensitized and produce immunoglobulin E (IgE) antibodies" (Johansson et al., 
2001). The World Allergy Organization has also recently published its recommended 
terminology (Flohr et al, 2004). There is no universal agreement about the definition of 
AD at present. Some prefer to define its atopic nature using IgE-specific antibodies and 
peripheral eosinophilia, which will develop in response to allergen exposure (Bos, 
2002;Turner, 2006;Boguniewicz and Leung, 2006); while others believe that AD defines 
a clinical state with characteristic criteria and features (Hanifin and Rajka, 1980;Williams 
et al” 1994). 
1.1.2 Epidemiology of atopic dermatitis 
The cardinal skin features of atopic dermatitis are erythematous and eczematous 
lesional skins, generalized dry skin, flexural lichenifications and papules accompanied by 
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intense pruritus and cutaneous hyperactivity (Kay, 2001). Most often, edematous lesions 
appeared on the skin surface during the acute phase, often excoriated with superficial 
crusts. When AD enters a chronic phase, the skin possess a complex phenotype with 
lichenified plaques, skin thickening and scaling, accentuated skin markings and post-
inflammatory hyper- or hypopigmentation. In paediatric patients, lesions are more 
common at the flexural joints, neck, forehead, cheeks, wrists and dorsa of limbs 
(Fleischer et ai, 2002). Up to now, 2 types of AD have been identified: extrinsic AD, 
affecting 70-80% of AD patients, presenting with sensitization towards environmental 
allergen and increased serum IgE levels; and the intrinsic form of AD, affecting 20-30% 
of the patients accompanied by low IgE levels and absence of any detectable allergen 
sensitization (Schmid-Grendelmeier et al., 2001;Novak et aL, 2003). 
The prevalence of AD in children is estimated at about 15%, which is a 3- to 4-
fold increase when compared with the trend in 1950s (Lewis-Jones, 2001) and is equally 
common in many other countries worldwide (Leung et al,, 1997;Foley et al” 2001). It 
develops early in life and becomes clinically evident in approximately 90% of children 
before 4 years of age (Emerson et al,, 1998). It is highly pruritic, chronic and is 
commonly present during early infancy and childhood. However, the disease can persist 
or start in adulthood (Johansson and Bieber, 2002). Several longitudinal studies suggest 
that AD predisposes to the development of allergic rhinitis and asthma and together these 
3 allergic disorders are often being recognized as ‘‘atopic triads", often with AD 
initializing the atopic march (Boguniewicz et al, 2003;Leung et al, 2004;Spergel, 2005). 
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1.1.3 Factors and triggers related to high risk of atopic dermatitis 
Genetics 
It has been proved that atopic dermatitis is genetically complex with strong 
maternal influence, with parental AD conferring a higher risk to offspring than parental 
asthma or allergic rhinitis, suggesting presence of AD-specific susceptibility genes 
(Cookson and Moffatt, 2002;Cookson, 2004;Brown and Reynolds, 2006). Different 
candidate genes have already been intensely investigated basing on their theoretical roles 
in pathogenesis of AD, including those lying in chromosome region lq21 showing genes 
specific for AD (Sugiura et al, 2005), 3q21 for CD 80 and 86 (Lee et al., 2000), 5q31-33 
for interleukin-I3 (Hummelshoj et al” 2003)， 1 l q l 3 for p-subunit of high-affinity 
receptor for IgE (FceRl) (Folster-Holst et al., 1998) and 17q25 for different gene and 
protein expressions between asthma and AD patients (Cookson et al., 2001;Ekelund et al., 
2006)，etc. However, a recent study in Chinese Population showed that there are not any 
associations of gene polymorphism patterns with expression of various cytokine levels 
(Chang et al, 2006). Nevertheless, there is still a long way to go to reach a consensus 
about the particular gene or genes that plays a key role in AD. 
Allergens 
Only the genetic factor is not able to give the whole picture for the causes and 
difference of atopic dermatitis (Williams, 2005). Most often, AD is also immunologically 
triggered by various environmental factors and allergens, for example, food allergens 
(Hon et al., 2006b). Food allergens would induce skin rashes in a significant proportion 
of children with moderate to severe AD (Sampson, 1999), and they would have an 
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elevated food-specific IgE levels with immediate positive skin test results (Lever et al, 
1998). Yet the dietary practices in different regions are different, thus showing a wide 
range of food allergen potency for different races of paediatric patients (Hon et al, 
2006b). 
Other common types of allergens include aeroallergens, which might cause 
pruritus and lesions after bronchial or intranasal inhalation (Tupker et al., 1996); and 
autoallergens, which the IgE or T-cells inside their own hosts will attack against, thus 
leading to immunological responses(Valenta et al., 2000;Kinaciyan et al., 2002). 
Staphylococcus aureus (S. aureus) 
Bacterial superinfection is common in children with atopic dermatitis (Ong et al., 
2002). It was reported that over 90% of the skin of the AD patients were colonized with S. 
aureus (Leyden et al., 1974)，and that a combination of treatment with both antibiotics 
and corticosteroids is more effective than corticosteroid therapy alone (Leyden and 
Kligman, 1977), suggesting the importance of such a bacterial infection. Colonization of 
S. aureus is important to the pathogenesis of AD. The bacterium produces superantigens 
to activate T-cell and macrophages to release cytokine, cause mast cell degranulation and 
enhance IgE-mediated reactions, thus influencing disease activity (Bunikowski et al, 
2000;Hon et al” 2005a). 
To summarize, the clinical phenotype of atopic dermatitis is determined by a 
complex interplay of the patients' susceptibility genes, their environment, skin barrier 
defects and various immune responses (Leung et al., 2004). 
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1.2 Pathogenesis of atopic dermatitis 
1.2.1 Nature of complexity of pathogenesis 
Although characteristic phenotypes make AD diagnosis to be simple and clear-cut 
(Barnetson and Rogers, 2002), its underlying pathophysiology mechanisms are very 
complex and debatable, and still not completely understood, although various cell types 
(e.g. lymphocytes, Langerhans cells, eosinophils, keratinocytes) and factors (e.g. 
cytokines, chemokines and immunoglobulins, particularly IgE) have been identified 
(Friedmann, 2002). 
1.2.2 Role of T-helper cell in atopic dermatitis and its paradigm model 
A commonly accepted immunologic pathway of AD pathogenesis is the T-helper 
1 cell / T-helper 2 cell (Th1/Th2) paradigm model (Abramovits, 2005). It starts from the 
differentiation of C D / T-helper lymphocytes (ThO) into ThI and Th2 cells. In AD 
patients, Th2 imbalance over ThI is prevailed and enhanced. Obsessive amount of Th2 
lymphocytes produce interleukins 4，5 and 13 (IL-4, IL-5, IL-13), which provide signals 
for B lymphocytes to activate mast cell, produce IgE and eosinophils, thus promoting 
type-1 hypersensitivity reactions in acute phase of AD (Jelinek, 2000;Friedmann, 
2002;Liu et al, 2006) (Figure 1.2). ThI lymphocytes produce IL-2 and interferon gamma 
(IFN-y), provoking delayed hypersensitivity reactions (Knoell and Greer, 1999). The two 
T-cells are mutually affected in the way that cytokines produced by Th2 suppress ThI 
activities (Abramovits, 2005), whereas IFN-y produced by ThI suppressed Th2 (Grewe et 
fl/.，1998) (Figure 1.2). Nevertheless, along the whole course of AD development from 
acute to chronic phase, the patients exhibit a biphasic T-cell pattern in which Th2 
5 
immune response predominance will switch to a more THl-like profile respectively 
(Leung, 2000). 
1.2.3 Nature of immunoglobuUn-E and its role in atopic dermatitis 
Basing on the above-proposed model, the majority of AD patients will therefore 
exhibit a hyper-production of immunoglobulin E as a result of the enhanced production 
of Th2 cytokines, particularly during the onset or the acute lesional phase (Abramovits, 
2005). Another source of IgE production is due to presence of Staphylococcus aureus 
antigens (Nordvall et al., 1992) and other superantigens (Marrack et al, 1990). It has 
been documented for long that IgE is the key mediator of AD and related 
hypersensitivities towards environmental allergens (Church et al.’ 1976), and a hallmark 
of atopic diseases (Burrows et al., 1989). Recent studies continue to prove that total 
serum IgE levels have significant epidemiological associations with early AD incidence, 
its subsequent prognosis (Perkin et al., 2004) and its severity (Laske and Niggemann, 
2004). Nevertheless, it has to be reminded that the above definition did not apply to the 
group of intrinsic form of AD patients, who exhibit normal values of total or specific IgE 
(Dotterud et al” 1995). 
IgE in peripheral blood forms crosslinks with antigens and triggers type I 
hypersensitivity reaction by inducing mast cells and basophils to release mediators, 
including histamines, which are the main pruritus-causing suspects (Abramovits, 2005). 
IgE also poses its significance on antigen-presenting cells (APCs) (Langeveld-Wildschut 
et al., 2000). The number of IgE-bearing Langerhans cells and inflammatory dendritic 
epidermal cells (IDEC) expressing FceRI also increases (Novak et al, 2001). Langerhans 
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cells provide a positive feedback loop by increasing the pool of Th2 cells, while FcsRI 
capture and internalize incoming antigens before they are processed to T lymphocyte in 
atopic skins (Santamaria-Babi, 2006). 
1.2.4 Chemokines in pathogenesis of atopic dermatitis: CTACK and TARC 
Another recent approach of the understanding towards the disease is by looking at 
relating chemokines. Chemokines are small, secreted polypeptides, regulating infiltration 
and migration of inflammatory lymphocytes into tissues through G-protein coupled 7-
transmembrane domains (Hijnen et al, 2004). They are pro-inflammatory cytokines, 
released by different cell types to function as chemoattractants and to guide cells 
involved in innate immunity. In AD, chemokines are responsible for guiding cutaneous 
lymphoid antigen T cells to the dermis (Morales et al, 1999). Their importance is 
substantiated by the fact that they express more granulocyte-macrophage colony-
stimulating factor (GM-CSF) (Pastore et al, 1997). GM-CSF initiates and maintains the 
chronic inflammatory process of AD by inducing generation, maturation and 
enhancement of APCs (Girolomoni and Pastore, 2001) and is therefore a central feature 
of AD. 
Among all chemokines, the thymus and activation-regulated chemokine (TARC) 
and cutaneous T-cell attracting chemokine (CTACK) are suspected to be important in AD 
pathogenesis and were shown to be specific for AD, which will increase with AD 
severity and decrease with successful treatment (Hijnen et al., 2004). Extensive studies 
on the 2 chemokines these few years further confirm their leading roles as biological 
markers for clinical management of the disease (Boguniewicz and Leung, 2006). The 
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receptor of TARC is richly expressed on skin homing, cutaneous lymphocyte antigen-
positive (CLA+) T lymphocytes (Campbell et aL, 1999). It is shown that TARC induces 
migration of Th2 cells (Imai et al., 1999), triggering a cascade of immune responses to 
tackle against allergic disorders. Such a theory is proved when TARC levels are found to 
be elevated in patients with AD, comparing with patients with psoriasis and healthy 
control subjects (Kakinuma et al, 2001). 
However TARC might nor be skin-specific and might be altered by other 
concurrent atopic disorders (Leung et al, 2002). CTACK is a skin-specific chemokine, 
shown to be useful in accessing adult AD severities (Kakinuma et al., 2003;Hon et al., 
2004a). It is a member of the conserved cysteines (CC) chemokine family, in the form of 
a ligand for CC chemokine receptor 10 (Kunke丨 and Butcher, 2002) and is responsible for 
localization of CLA+ memory T cells to skin, thus regulating T-cell trafficking in 
cutaneous levels (Morales et al., 1999). 
1.2.5 Role of antimicrobial peptides and innate immunity 
Antimicrobial peptides (AMP) are an integral part in mediating human innate 
defense. They are expressed by epithelial or adjacent cells, being secreted onto skin 
surface in response to inflammation and perform antimicrobial activity against 
microorganisms, including Staphylococcus aureus (Ong et al., 2002). Classes of AMP 
include human cathelicidin LL-37, human ^-defensin classes and others (Gallo and 
Huttner, 1998). In AD patients, the innate immune mechanism is impaired. Low levels of 
AMP will therefore promote colonization of S. aureus on nonlesional atopic skin, and 
worsen AD (Rieg et al., 2005). 
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1.3 Measurements of atopic dermatitis severity and quality of life impairment 
1.3.1 Scoring of atopic dermatitis severity and the SCORing Atopic Dermatitis Index 
Despite the current ambiguities in understanding of AD, clinicians and 
researchers are seeking for the most valid, reliable, and relevant outcome measures to 
ensure the effectiveness of healthcare interventions (Charman et al., 2003). 
Due to the fact that AD is a syndrome of related clinical features arising in 
response to a number of endogenous and exogenous factors, there is not a sole definite 
marker to reflect definite severity of eczema. Therefore measurements are mainly based 
on a collection of signs and symptoms (Finlay, 1996). A review of 93 randomized 
controlled AD-related clinical trials revealed that scoring of clinical signs was the most 
widely adapted outcome measure (in 91% of trials) (Charman et al,, 2003). According to 
the review, the most widely used clinical scoring system was the SCORing Atopic 
Dermatitis (SCORAD) index (1993), a score basing on a set of 24 major and minor 
clinical diagnostic criteria of AD proposed by Hanifin and Rajka (Hanifin and Rajka, 
1980) (Table 1.1). In SCORAD, 60% of the total score was based on clinical signs and 
20% is based on disease extent, with only 20% weighting for patient reporting subjective 
symptoms of pruritus and sleep loss (Kunz et al, 1997;Gelmetti and Colonna, 2004). 
1.3.2 Quality of life measurement 
While a lot has been discussed on scoring of AD, quality of life (QoL) has always 
been neglected, with only 3% of reviewed clinical trials had proper measurements 
(Charman et al,, 2003). The impact of life quality impairment of AD is a very important 
manifestation as it has both a high rate of prevalence and is often more severe and long-
lasting than any other childhood skin disorders (Finlay and Burgdorf, 2004). It can cause 
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severe psychological problems and can be overwhelming not only to the patients, but the 
entire family (Barnetson and Rogers, 2002). Moreover, SCORAD has its own 
shortcomings. Although SCORAD is one the best validated systems and is suited for 
clinical trials, it is too complicated and time consuming for routine clinical use (Gelmetti 
and Colonna, 2004). In patients' point of view, an objective clinical scoring system, like 
SCORAD, is also not necessary to provide a clinically all-rounded meaningful reflection 
of disease severity, with SCORAD focusing QoL impairment on pruritus and sleep loss 
only (Charman et al, 2005). Therefore patient-based symptom measures and QoL 
scoring systems have also been emphasized over the past decade for providence of 
additional information (Jordan, 1983;Lindstrom and Kohler, 1991 ;Lewis-Jones and 
Finlay, 1995;Holme/ a l , 2006). 
1.3.3 The Children's Dermatology Life Quality Index (CDLQI) 
Among all, the Children's Dermatology Life Quality Index (CDLQI) is one of the 
most standardized and objective QoL measures (Lewis-Jones and Finlay, 1995). It 
consists of 10 questions, designing for use in children ages 5-16 years. It is self-
explanatory and can be filled up by the child with minimum help from the parent or 
caretaker. Questions in the index cover over the areas of symptoms and feelings, daily 
activities, leisure, impact during school or on holiday, personal relationships, and sleep 
and treatment compliance. The CDLQI has been validated and translated into Cantonese 
to suit local clinical and community epidemiology usage in Hong Kong (Chiih, 2003). 
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1.4 Pruritus in atopic dermatitis and its underlying mechanisms 
1.4.1 Introduction to pruritus 
Pruritus, or itch, has for long been defined as a poorly localized, non-adapting, 
usually unpleasant sensation that provokes desire to scratch (Rothman, 1941) and is a 
major important symptom of atopic dermatitis, constituting a predominant diagnostic 
criterion. It is one of the most complex and multi-dimensional sensations, and its research 
progress is slow (Greaves and Khalifa, 2004). Pruritus is a distressing sensation or even a 
psychological disorder that substantially impair the quality of life (Finlay and Burgdorf, 
2004). AD patients have a lower threshold of itch than normal non-infected skin and are 
inherently itchy (Morren et al., 1994). Most often, the sensation of pruritus impairs the 
quality of life in numerous manners and extent (Daud et al., 1993;Jemec and Wulf, 1996). 
Pruritus can be evoked or augmented by a vast variety of physical, chemical and 
pharmacological stimuli (Table 1.2). Among all, peripheral pharmacological mediators 
plays a key role in the production of itch in atopic dermatitis (Greaves, 2004). It has also 
been reported that chronic psycho-emotional stress and worry would involve cortical 
centers and activate the hypothalamus-pituitary-adrenal axis, thus enhancing sensation of 
pruritus (Slominski and Wortsman, 2000;Paus et al, 2006b). 
1.4.2 Difference between pruritus and pain 
There always exist controversial arguments on the actual pathophysiology of 
pruritus, which, as a result, hinder researchers on tackling this important frustrating 
symptom of atopic dermatitis (Yosipovitch et al” 2003). While itch and pain are 
transmitted in different specific peripheral C-units and central afferent pathways (Baron 
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et a l , 2001)，there exist complex interactions and similarities between pruritus and pain 
(McMahon and Koltzenburg, 1992;Schmelz, 2005), only differ at the outcome: pain 
brings out a reflex withdrawal, whereas pruritus leads to a chronic reflex of scratching. 
Another group of scientists distinguish itch and pain as 2 completely different sensations 
by using electrical stimulation via a microelectrode implanted in afferent nerves of 
patients (Hsieh et al” 1994). Both pain and itch can be reduced by soft rubbing, which 
activates fast-conducting, low-threshold nerve fibers (Bromm et a!., 2000). 
L4.3 Pathogenesis and neuronal pathways of pruritus 
That pain and itch are transmitted along the same nerve pathways proposed before 
has been prevailing until recently, when dedicated itch-transmitting neurons were 
discovered at both the peripheral and central afferent pathways (Schmelz et al., 
1997;Andrew and Craig, 2001b) (Figure 1.3). The most widely accepted theory of 
neuronal pathophysiology of pruritus nowadays is an independent, yet almost identical 
neural pathway of pruritus and pain sensations (Yosipovitch et al, 2003). Inflammatory 
skin lesions of AD patients would trigger the dermal mast cells in order to form or release 
a bunch of mediators, including neuropeptides, neurotransmitters, proteases, arachidonic 
acid derivates, cytokines and skin-infiltrating T-cells, etc., at cutaneous region (Stander 
and Steinhoff, 2002) (Figure 1.4). A more detailed collection of physical, chemical and 
pharmacological stimulations is listed in table 1.2. Afferent itch-dedicated polymodal C 
neurons were discovered upon induction of itch by histamines (Schmelz, 2001), which 
are distinct form pain-transmitting fibres. A signal is generated upon binding of various 
mediators to pruritoceptive endings of these C fibres and a signal is generated. The signal 
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is being transmitted at a slow conduction velocity via specific secondary transmission 
neurons in the lateral spinothalamic tract of the dorsal horn, projecting to the thalamus for 
interpretation of sensation (Andrew and Craig, 2001a). Pruritus signals were then found 
to co-activate the anterior cingulated cortex, inferior parietal lobe, supplementary motor 
area and also several forebrain regions in the brain (Darsow et al, 2000;Drzezga et al., 
2001;2001). 
The mechanisms of pruritus mentioned above were mainly focused on 
inflammatory sites. Yet there also exists itching related to chronic lichenification from 
excessive drying of the skin in AD patients without noticeable lesions. Emollients are all 
that are required for management of xerosis and will be inadequate where inflammatory 
changes are responsible for the itching. A clear difference between these 2 sorts of 
pruritus has to be distinguished. 
1.4.4 Neurogenic itch 
However the story is not so straightforward. It has been found out that non-
lesiona! eczematous skin evokes a significantly lower degree of pruritus than lesional 
regions. The complex combination of a inhibitory degree of afferent neuronal sensation 
in non-lesional skin and elevated itch response in lesional region will lead to a defective 
modulation of itch traffic, thus enhancing itch process in the CNS, leading to central 
sensitization and amplified itching perception, hence exemplifying itching and generating 
an important category of neurogenic itch (Twycross et al., 2003;Yosipovitch et al,, 
2003;Greaves and Khalifa, 2004). It has also been proved that in cases of chronic skin 
inflammation, activation of nociceptors not only provokes itch, buy also facilitates itch 
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processing in the spine, resulting in touch-evoked pruritus around an itching site (Paus et 
al., 2006a). In such cases, misinterpretation of even normally painful stimuli as itch will 
occur (Ikoma et al, 2003). The idea of neurogenic itch explains the causation of 
persistent itching sensation by changes in non-itchy mechanical stimuli (alloknesis), such 
as sweating and temperature change (Heyer et al, 1995). 
1.4.5 Role of histamines in pruritus 
Among all mediators, histamines have long been believed as the major peripheral 
mediator in pruritus since the very beginning of skin research (Lewis, 1927). Traditional 
approach of pruritus treatment relied heavily on antihistamines, however scientists also 
argued its usage based on the result of little or no effect of histamine receptor antagonists 
in relieving itch, especially in AD (Rukwied et al., 2000). It has also been argued that the 
effectiveness of antihistamines are due to their sedative actions or other poorly known 
pharmacological properties rather than peripheral histamine-blocking activity (Behrendt 
and Ring, 1990;MLinday et al, 2002;Rees and Murray, 2005). 
1.4.6 Substance-P 
Due to the non-specific nature of histamines, such measurements are not 
satisfactory in determining the extent of pruritus in AD patients. Therefore scientists 
continue to search for other key mediators. One of the classes of mediators is tachykinins, 
which are located in unmyelinated sensory nerve fibres in skin. Among them, substance P 
(SP), which is a 11-amino-acid neuropeptide, causes redness, whealing and itching 
(Hagermark et al,, 1978;Jorizzo et al, 1983) and is important for direct communications 
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between mast cells and nerve fibres (Suzuki et al., 1999). In AD patients mast cells play a 
pivotal role in triggering acute hyperresponsiveness once received signal from Th-2 cells. 
The vast amount of tryptase secreted by activated mast cells during acute inflammation 
will cleave proteinase-activated receptors 2 (PAR2), which are richly expressed around 
afferent nerve terminals. SP will be produced at the dorsal root ganglion of nociceptor C 
fibres upon such a cleavage, hence transmitting and amplifying pruritic signals (Steinhoff 
et al., 2000). High concentrations of SP will also bind back to the specific NKl receptors 
of the mast cell, causing their degranulation and subsequent release of pruritic mediators 
(Yosipovitch et al, 2003), including tumor necrosis factor - a (TNF-a), which will further 
stimulate the endings of nociceptors (Cocchiara et al, 1999). Thus a positive feedback 
loop is generated, amplifying signals to a greater extent. 
1.4.7 Brain-derived neurotrophic factor and other recent mediators in pruritus 
Another important pruritogenic mediator that is under heavy investigation is 
brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family 
(Leibrock et al” 1989) richly found in the neurons (Lewin and Barde, 1996). 
Neurotrophins were found to have mediatory effects upon inflammatory conditions 
(Toyoda et al., 2002), and were also suspected in regulating important immune cells of 
AD, including 丁-cells (Kerschensteiner et al； 1999) and eosinophils (Raap et al., 2005). 
Its multifactorial effect may therefore shed a new light on the understandings of pruritus. 
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1.5 Scratching, nocturnal scratching and sleep behavior in atopic dermatitis subjects 
and related research progress 
1.5.1 Overview 
Pruritus and sleep problems are directly interrelated and AD patients with severe 
itching are prone to difficulties falling and staying asleep over a whole night than those 
without such problems (Stores et al., 1998;Finlay and Burgdorf, 2004). The primary 
reason for such a relationship between pruritus and sleep loss is due to the change in 
temperature based on the concept of alloknesis (Heyer et al., 1995), with a warmer 
environment in bed being a mechanical stimulation to pruritus-specific C neurons. In 
paediatric patients, their sleep abnormalities is a combination of initialization of sleep and 
failure in maintaining a tight sleep throughout, leading to poor sleeping conditions, with 
consequent negative impact on their schoolwork, impairments on their temper and their 
family relationships during the daytime (Reid and Lewis-Jones, 1995;KIein and Clark, 
1999). Parents may also suffer from sleep deprivation and exhaustion (Reid and Lewis-
Jones, 1995). As a result, measurements of both parameters serve as an important role in 
evaluating disease severity and QoL impairment of AD patients (Finlay and Burgdorf, 
2004). 
The extent of sleep loss was assessed traditionally by visual analogue scales or 
questionnaires, both of which relied heavily on whether both subjects and their caregivers 
were able to relate their perceived experience accurately (Hon et al., 2003). However, 
self-reports are always inaccurate because nocturnal sleep disorder is not a conscious 
activity. Even when conscious, the required information was always poorly remembered 
when combining the therapeutic effects of sedative drugs (Benjamin et al, 2004). 
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Bypassing the ambiguity, scientists use the extent of scratching as another important 
quantification parameter to define itch, basing on the fact that scratching is the main 
response being provoked by the itching sensation. 
1.5.2 Interrelationship between pruritus, scratching and sleep disturbance 
In order to use scratch measurement to replace itch measurement, their 
interrelationship have to be clarified. Scratching is a voluntary motoric action to 
counteract the pruritic sensation by application of slightly painful stimuli (Paus et al,, 
2006a). It is the primary action for alleviating itch in patients (Greaves and Khalifa, 
2004). The action of scratching or rubbing will stimulate a group of touch and pressure-
conducting myelinated A neurons via low threshold mechanoreceptors. Such stimulation 
is antagonistic to that of pruritus, thus surrounding itch processing by inhibitory neuronal 
circuits in substantia gelatinosa in the grey matter of the spinal cord is leveled off 
(Kirchner et al” 2002). Hence the modulatory signal towards dorsal horn is reduced, and 
so does the perception of itch (Wall and Melzack, 1995;Greaves and Wall, 1996). Last 
but not least, vigorous scratching would generate new wounds, thus triggering a cascade 
of inflammatory mediators, leading to a new wave of pruritus sensation through the 
mentioned neurogenic pathways. The itchier the patients get, the more they scratch 
consequently, and thus a vicious cycle is generated. Therefore the relationship of itch and 
scratching are inseparable, and measurement of scratch would be a sounding approach for 
replacing subjective pruritus measurement, basing on the argument that the higher the 
intensity of pruritus, the more the patients will scratch in order to alleviate the sensation. 
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Among all aspects of life quality that are impaired by atopic dermatitis, sleep 
disturbance by pruritus and nocturnal scratching is the most important area of research 
(Stores et al., 1998;Reuveni et al., 1999;Chamlin et al., 2005). Pruritus is always 
associated with sleep disturbances in children (Dahl et al., 1995;Stores et al., 1998). 
Moreover, difficulty falling asleep and night waking in children with AD correlate with 
daytime behavioral problems (Dahl et al” 1995). As a result, sleeping behavior of AD 
patients should never be neglected. 
1.5.3 Current methodologies in nocturnal scratching and sleep quality measurement 
Despite its significance in exacerbating AD situation, scratching due to pruritus is 
difficult to be documented in the home environment of patients (Rees and Laid law, 
I999;Hon et al., 2006a). Traditional assessments of sleep and nocturnal pruritus in 
children with AD include infrared videotaping (Ebata et al., 1996) and overnight 
polysomnography (PSG) (ncoli-Israel et al, 2003), which has been applied on AD 
patients and a recording of overnight sleep physiology, is marked by frequent awakenings 
associated with scratching episodes and an overall reduced sleep efficiency is observed 
(Stores et al., 1998). However, the practices are rather difficult to be carried out in a 
home-base environment for routine, continuous and repetitive measures (Ebata et al, 
2001). The patients often find them uncomfortable (Hon et al,, 2006a). Another 
measurement approach focused on movement detection devices and meters that can 
record and quantify scratch, the objective correlate of itch. Such a research direction 
began in 1970s and is still ongoing today (Savin et al, 1973;Felix and Shuster, 
1975;Bender et al, 2003;Benjamin et al, 2004;Hon et al., 2006a). Such devices have 
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become more computer-friendly since the establishment of actigraphy techniques (Cole et 
al., 1992), which is being generally defined as a method for measurement of activity 
through small, wristwatch-like devices (Acebo and LeBourgeois, 2006). Actigraphy 
allows easy transfer of data and signals from the device into computer for analysis. 
Scratching movement can also be expressed in a visual pattern with contours. Such 
accelerometers have been validated against the gold standard of infrared videotaping of 
children with AD in their own homes (Benjamin et al, 2004). Adequate agreement 
between actigraphic data and sleep scored from PSG recordings were also met (Sadeh 
and Acebo, 2002). Yet there still leaves a drawback that it is very difficult to distinguish 
between scratching activity and limb restlessness from the whole bunch of data obtained 
(Bringhurst et al,, 2004). It is difficult to discard those data that are not related to sleep, 
i.e. artifacts recorded by actigraphy (Acebo and LeBourgeois, 2006). Even for recording 
at night only, the dissociation among the entirely different sorts of nocturnal activities is 
not possible. To date, there have been no standardized protocols for sleep recording, data 
acquisition and other related variables. New users often find it difficult to obtain a 
published validity study for these new devices (Acebo and LeBourgeois, 2006). 
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Major criteria 
• Pruritus 
• Typical morphology and distribution: 
Flexural lichenification or linearity in adults. Facial and extensor 
involvement in infants and children 
• Chronic or chronically relapsing dermatitis 
• Personal or family history of atopy 
(asthma, allergic rhinitis, atopic dermatitis) 
Minor criteria 
Xerosis 
Ichthyosis / palmar hyperlinearity / keratosis pilaris 
Immediate (Type I) skin test reactivity 
Elevated serum IgE 
Early age of onset 
Tendency towards cutaneous infections 
Tendency towards nonspecific hand or foot dermatitis 
Nipple eczema 
Cheilitis 
Recurrent conjunctivitis 
Dennie-Morgan infraorbital fold 
Keratoconus 
Anterior subcapsular cataracts 
Orbital darkening 
Facial pallor / facial erythema 
Pityriasis alba 
Anterior neck folds 
Itch when sweating 
Intolerance to wool and lipid solvents 
Perifollicular accentuation 
Food intolerance 
Course influenced by environmental / emotional factors 
White, dermographism / delayed blanch 
Table 1.1 Diagnostic criteria for atopic dermatitis in children and adults. A patient should 
have at least three major criteria accompanied by at least three minor ones. (Hanifin and 
Rajka, 1980) 
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Physical /Mechanical 
Light touch 
Stroking 
Vibration 
Mild heat 
Electrical 
Chemical 
Acids 
Alkali 
Other irritants 
Pharmacological 
Histamine 
Histamine liberators 
-Morphine 
-Codeine 
-Compound 48/80 
Serotonin (5-hydroxytryptamine) 
Prostaglandins 
Platelet-activating factor 
Kallikrein 
Cytokines 
-Interleukin-2 
Proteases 
-Trypsin 
-Papain 
-Mucunain 
Tachykinins 
-Substance P 
Calcitonin gene-related peptide 
Opioid peptides 
"P-endorphin 
-Leu-enkephalin 
-Met-enkephalin 
Table 1.2 Main Classes (with examples) of externally applied factors which cause itching 
(Greaves, 2004). 
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Atopic I Non-atopic | Allergic | Non-allergict \ 
•Includes nummular (discoid) eczema, photosensitive dermatitis, and 
seborrhoeic dermatitis 
tNon-allergic contact dermatitis is also known as irritant contact dermatitis 
Figure 1.1 Subgroups of dermatitis. Some patients may have a combination of subgroup 
types. (Brown and Reynolds, 2006) 
Figure 1.2 Differentiation of T-helper (Th) lymphocytes (Friedmann, 2002). 
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Figure 1.3 Neurophysiology of itch (Yosipovitch et al., 2003). Signals are generated first 
at the nerve endings in cutaneous region, then pass through the unmyelinated slow-
conducting C fibres, dorsal root ganglion and the transmission neurone. 
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Figure 1.4 Cross-talk between cutaneous afferent C neuron terminals and dermal mast 
cells (Yosipovitch et al., 2003). A collection of mediators are released from dermal mast 
cells, which bind to pruritoceptive endings of C fibre endings, thus generating signals of 
pruritus. 
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Chapter 2 
Objectives 
The primary objective of this project was to investigate the possibility of using an 
alternative method to measure pruritus, in particular nocturnal scratching in paediatric 
patients suffering from atopic dermatitis (AD). The methodology should be easy to be 
carried out at the subject's own home, where the routine sleeping conditions could be 
reflected. The data obtained had to be objective and be able to truly reflect their sleeping 
conditions in home-based environment rather than in completely unfamiliar conditions. 
Objectivity was emphasized because the traditional questionnaires or reports, in the form 
of a sleep diary, relied heavily on subjective reporting from either patients or caregivers. 
Nevertheless, these traditional methods would still be performed for comparisons with 
the new measurement. Examinations were done by one investigator only throughout to 
avoid intra-observer variability. In addition, diagnosis of AD for all patients would only 
follow one criterion throughout the whole study, i.e. the criterion proposed by Hanifin 
and Rajka (Hanifin and Rajka, 1980) (Table 1.1) and by performing measurement of AD 
severity using one scoring system, the widely used SCORing Atopic Dermatitis 
(SCORAD) index (Kunz et al, 1997). 
The device used in the new methodology should be non-intrusive to the patients 
in the long run. As for validation purpose, blood was taken throughout the whole study to 
obtain a series of objective laboratory markers to look for any close relationship with the 
data obtained. To achieve this, written consents were taken from the participants and the 
whole protocol was approved by the Clinical Research Ethics Committee of the 
university. Various relationships among the data obtained from the new methodology 
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with the SCORAD index and all objective clinical markers were investigated by 
statistical means to look for significant inter-relationships. 
The secondary objective was to test the device in clinical trials through 
investigating the efficacies of various AD medications, especially on the alleviation of 
sleep problems and improvements in quality of life. In particular, medications other than 
traditional therapies of topical corticosteroids, such as traditional Chinese herbal 
medications and calcineurin inhibitors (e.g. tacrolimus ointment), would be used and their 
effectiveness would be discussed in depth below. Pruritus involved in diseases other than 
AD, if any, was also one of the areas of interest of this study. 
By investigating all of the parameters mentioned above, we aimed at defining a 
new paradigm for itch measurement, clinical manifestations of itch and its impairment 
with quality of life on AD patients, and the application of our findings in certain 
medication trials. All these were done to achieve the ultimate aim: to take a step in 
relieving the chronic suffering of children irritated by itch. 
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Chapter 3 
Methodologies and Materials 
3.1 Validation of a new methodology / device 
3.1.1. Device selection 
Based on the criteria set for a new device mentioned above, various measuring 
devices were considered including accelerometers, infrared videotaping and overnight 
polysomnography. Digitrac® Limb Movement Recorder (IM Systems, Baltimore, MD) 
(Figure 3.1) was chosen at the end. It is a light-weight, self-contained, wrist-worn device 
that can be easily worn on the limb even for young patients. This is particularly useful in 
our study for young patients to assess their nocturnal scratching behavior in a home-
based environment. It is completely ambulatory and no wire connection is necessary 
during recording of motion. With the help of a piezoceramic acceleration sensor, the 
device can record not only the amplitude, but also frequencies of limb movements in a 3-
dimentional manner. The Digitrac Limb Movement Recorder has been used in sports 
science research and this was the first time for it to be applied in the field of medical 
science. 
3.1.2 Study design 
Patients aging 2-18y, with AD diagnosed according to the Hanifin (Hanifin and 
Rajka, 1980) criteria, were recruited from the paediatric dermatology outpatient clinic of 
our university-affiliated teaching hospital. Severity and symptomatology (pruritus and 
sleep loss) of AD in the preceding three days were evaluated with the aid of the 
SCORAD index (Kunz et al, 1997) (Figure 3.3). The components in the SCORAD 
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scores provided information on the extent, types and severity of eczematous lesions. 
Examinations were performed by only one investigator to avoid any intra-observer 
variability. Subjects with a SCORAD score > 15 were enrolled into the study. Subjects 
were excluded if the patients' caregivers failed to provide information regarding pruritus 
or sleep loss, or if obvious parasomnias were evident from history. Any sedative sleeping 
medications were also prohibited one week prior to the study and during the night of 
motion recording. Normal children seen at the clinic with non-inflammatory and non-
itcliy skin conditions as well as healthy children from hospital staff were recruited as 
controls. All subjects were then instructed to wear the device on their dominant wrist 
before going to bed. 
In the pilot testing, Digitrac was found to be able to obtain data on a wide 
spectrum of frequencies of wrist movements and quantify movements in term of 
acceleration or g values. The monitor was programmed to record limb motion between 10 
p.m. and 8 a.m. in the next morning, only the data from the time- the patients had got in 
were analysed. In order to avoid any artifacts being analyzed, patients were also required 
to give a verbal report on the time getting asleep and waking up. All data were stored 
automatically into a flash memory within the recorder, and the device was collected the 
next day with the data being downloaded to computer using the program DigiTrac 3.9 
(IM Systems, Baltimore, MD) (Figure 3.2). Wrist activities were expressed in unit of 
average value of acceleration (g min"'). With the aid of the program, 3-dimensional 
frequency-specific contourgraphs of limb motions were obtained, and the data was 
expressed in mg min' ' . 
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The average limb activities frequency contour spectra of AD patients and controls 
were assessed to determine any significantly different patterns between the two parties by 
performing student t-tests. A Pearson's correlation test among the subjective and 
objective component of the SCORAD scores and Digitrac data of the patients were also 
performed for any significant relationship. In particular, focus will be put on comparing 
the objective data recorded by the device and the subjective symptom scores. 
3.1.3 Validation of the Digitrac with laboratory markers 
As for the validation of Digitrac, laboratory markers were also used for cross-
reference. The necessity of blood-taking has also been included in the written consent 
mentioned previously. Venous peripheral blood (PB) was collected from recruited AD 
patients, stored in serum separator and EDTA blood collection tubes (Greiner Bio-One, 
Kremsmuenster, Austria). Serum concentration of total IgE was measured by micro-
particle immunoassay (IMx analyser, Abbott Laboratories, Abbott Park, IL), and results 
were logarithmic transformed before analysis. Eosinophil counts in PB were enumerated 
using Coulter STKS counter (Beckman-Coulter, Miami, FL). Both assays were done 
immediately after blood collection. 
The rest of blood collected was centrifuged at 4 � C and 204Ixg for 10 minutes 
within 2 hours after collection using a Hi mac CR7 centrifuge (Hitachi Koki, Ibaraki, 
Japan). Serum (from serum separator tubes) and plasma (from EDTA tubes) obtained as 
the supernatant after centrifugations of the blood samples were stored at -80°C until 
analysis of markers in one batch. 
Thymus and activation-regulated chemokine (TARC) and cutaneous T-cell 
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attracting chemokine (CTACK), being chemotactic factors for AD-associated leukocytes, 
are used as objective laboratory parameters to validate Digitrac in this study. Plasma 
concentrations of TARC and CTACK were measured in duplicates by two enzyme-linked 
immunosorbent assays (ELISA) (R&D Systems, Minneapolis, MN) (Figure 3.4a). The 
lower limits of detection for TARC, CTACK were 7 and 1.5 pg ml'', respectively. 
The two ELISA protocols were similar. During the actual assay, 100 p.! of assay 
diluent was added to each well of a microparticle plate pre-coated with monoclonal 
antibody specific for the markers, followed by the addition of 50 |j.l standards or samples 
into each well. The plate was incubated at room temperature for 2 hours, by the time any 
TARC / CTACK present in either samples or standards were bound by the immobilized 
antibody on the plate. After aspiration by washing buffer to remove unbound substances, 
200 |j.l of enzyme-linked monoclonal antibody specific for the markers to be studied was 
added into the wells. The whole plate was again incubated for 2 hours to allow for the 
formation of sandwich conjugates between the enzymes and chemokines present. 
Following a wash to remove any unbound antibody-enzyme reagents, 200 [i\ of a solution 
of hydrogen peroxide and tetramethylbenzidine was added to the wells and color was 
allowed to develop within 30 minutes in proportion to the amount of TARC / CTACK 
bound in previous steps. The color development was stopped by addition of 50 stop 
solution (2N sulfuric acid) and the intensity of the color of each well is measured with a 
microplate reader with a fiQuant plate reader (Bio-Tek Instruments, Inc., Winooski, Vt.) 
(Figure 3.4b), under a wavelength of 450 nm, with wavelength \ correction at 540 nm. A 
standard curve of TARC / CTACK concentrations was obtained and the actual 
concentrations of each well were then calculated basing on the standard curve plotted and 
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dilutions of samples done for the assay. 
3.1.4 Factor and statistical analysis 
In order to explore the correlations among different subjective and objective 
parameters and to confirm they are independent dimensions in assessing AD severity, 
exploratory factor analysis was performed using the Statistical Package of Social 
Sciences (SPSS) (v. 13.0, SPSS Inc., Chicago, IL, USA). Bartlett's test of sphericity was 
used to assess the possibility for performing factor analysis, and Kaiser-Meyer-Olkin 
(KMO) measure of sampling adequacy was also evaluated. A high KMO (maximum 1.0; 
minimum acceptable 0.5) indicates that data is likely to factor well since correlations 
between pairs of variables can be explained by the other variables (low partial correlation 
coefficients). Correlation coefficients were analyzed by principal component analysis and 
subsequent rotation according to the standard varimax criterion (Stevens, 1996;2002). It 
was decided a priori that the number of factors in the varimax rotation would be based on 
the number of eigenvalues > 1.0 in the principal component analysis (Cattell, 1966). 
All data obtained was analyzed with the program SPSS 13.0. Data were expressed 
as means with standard deviations (SDs) or standard errors of mean (SEMs). Parametric 
statistical tests were performed if the data showed normal distribution, Pearson 
correlations were performed to look for any significant relationship between two 
variables. A two-tailed p-value of less than 0.05 was considered to be statistically 
significant. 
31 
3.2 Application of Digitrac in traditional Chinese herbal medication (TCHM / TCM) 
clinical trial 
3.2.1 Current AD treatment using corticosteroids and their drawbacks 
The mainstay of AD treatment has remained unchanged for several decades, and 
still relies heavily on corticosteroids (CSs) nowadays (Judge, 2005) in both systemic and 
topical formulations. However, CS treatment is not specific enough. Prolonged usage of 
CSs have a wide range of suspected immunomodulatory / immunosuppressive effects 
including suppression of cytokine synthesis, leukocyte chemotaxis and adhesion 
molecule expression (Pucci et al, 2000). CS is also linked with potential threats of 
deranged metabolism, growth suppression and increased susceptibility to infection. 
Potent topical CS application can result in significant suppression of the hypothalamic-
pituitary-adrenal axis, altered linear bone growth, or even growth retardation in children 
(Ellison et al” 2000;Schachner et al, 2005). These adverse effects together with the 
emotional fear of long-term use of topical steroids have induced topical steroid phobia in 
many patients throughout the world (Charman et al., 2000). This often drives patients to 
seek for alternative therapies, and traditional Chinese herbal medications (TCM) is one of 
the most commonly used treatments (Hon et al, 2004b). 
•S.2.2 Recent trend on TCM treatment 
Traditional Chinese Medicine focuses on the importance of catering the therapy to 
suit the different needs of each individual, whereas most Western medication trials are 
standardized and stress on "average" efficacy in large, double-blind, placebo-controlled 
studies. This difference hinders TCM research in both inpatient and outpatient settings 
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(Koo and Desai, 2003). Although TCM is widely used in many Asian societies, its 
beneficial effects on children with AD have not been consistently demonstrated and 
undesirable side effects have been reported (Hon et al.’ 2004b). 
Currently there are only a few well-documented studies on the application of 
Chinese herbal therapy in AD (Sheehan et al., 1992), while none of the available works 
was well-validated with combinations of objective measures, especially for pruritus. 
Therefore, the next step in this study aimed at evaluating the clinical effects of TCM on 
AD severity, pruritus and life quality of the patients by objective measures, including the 
application of the Digitrac movement recorder. Possible adverse events of our TCM on 
haematologic, hepatic and renal functions, if any, were also recorded to ensure safety of 
the medications. 
3.2.3 Study plan 
The TCM formula used in the trial was named as Pentaherbs (Figure 3.5). It was 
synthesized in the form of capsules for the convenience of the patients and to eliminate 
the taste of bitterness. The original formula was: Flos lomcerae (Jinyinhua) 2 g, Herba 
menthae (Bohe) 1 g, Cortex moutan (Danpi) 2 g, Rhizoma atractylodis (Cangzhu) 2 g and 
Cortex phellodetidri (Huangbai) 2 g (total 9 g of raw herbs daily). The extraction rate 
from this raw herb was around 18%-20%, and the extracted portion was made into six to 
seven capsules. The dose calculation was based on the assumption that patients had to be 
old enough to swallow the capsules without difficulty (between 7 to 12 years of age). The 
capsule was manufactured, packaged and labeled by the Chinese Medicine Industry 
Development Centre of the Hong Kong Institute of Vocation Education, using Good 
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Manufacturing Practice (GMP) standard. The optimal composition of each herb included 
was standardized prior to manufacturing. The powder was formulated into uniform dose 
capsules under the supervision of the Clinical Trials Section, Institute of Chinese 
Medicine of The Chinese University of Hong Kong according to established procedures. 
Before the clinical trial, these capsules were assessed by the Institute of Chinese 
Medicine for the presence of heavy metals, microbial products and residual pesticides to 
ensure that the quality and safety requirements were met. 
Prior to the study, patients were required to complete the Children's Dermatology 
Life Quality Index (CDLQI) in the form of a questionnaire in order to assess the subjects' 
life quality impairment (Lewis-Jones and Finlay, 1995) (Figure 3.6). The CDLQI score 
consists of 10 questions, with each question scoring from 0 ("not at all") to 3 ("very 
much"). The maximum possible score of the whole questionnaire is 30 and the minimum 
score is 0. The higher the score is, the more the quality of life (QoL) is impaired. To 
facilitate a better understanding of the questionnaire to the subjects, a Cantonese-
translated version was used (Chuh, 2003) (Figure 3.7). 
Participants underwent a 4-week, run-in period. During this period, their baseline 
dietary intake, emollient and drug use, and information on severity of AD were collected. 
AD of the subjects was diagnosed according to the Hanifin criteria (Hanifin and Rajka, 
1980), and would be excluded if they had active concurrent disease other than allergic 
diseases such as asthma and allergic rhinitis, or if they had received psoralen ultraviolet A 
(UVA) treatment within the previous 8 weeks. The SCORAD index was performed by the 
investigator at baseline (1993). A SCORAD score of less than 15 was considered to be 
too mild to be enrolled into the study. The patients would then be given three Pentaherbs 
34 
capsules (250 mg active herbs each) twice daily for a consecutive 12-week; period. 
Physicians at the Institute of Chinese Medicine of our university considered this dosage 
as suitable for a wide range of age groups. Correct use of the medications was explained 
to each subject and their parents, thus ensuring that they were compliant to the treatment 
regimen and proper use of medications. Enrolled subjects were followed up once every 6 
weeks. Each patient was given an Eczema Diary at the beginning of the trial for recording 
daily symptoms and adverse effects, if any. The severity of AD was assessed with the 
SCORAD index during each visit, and this served as the primary outcome of the study. 
Patients were allowed to continue routine relieving medications like CS and 
antihistamines throughout the study yet these concurrent treatments had to be kept 
unchanged throughout the study. Adherence to the study regimen was evaluated by 
comparing the number of capsules returned with the number recorded as taken in the 
Eczema Diary at the end of the trial (Appendix I). 
Subjects were instructed to wear the device on the dominant wrist before getting 
to bed on the first night of the baseline of the trial. The setting, collection and analysis of 
data from the device followed the ones used in the validation stage. The same procedure 
was being carried out during the end of the study. 
3.2.4 Validation with laboratory markers, Staphylococcus aureus infection and 
statistical analysis 
As for the clinical markers, PB was obtained during the clinic visit at baseline and 
the completion of the study. IgE levels and eosinophil counts were measured using the 
same protocol mentioned above. Plasma concentrations of CTACK and TARC were 
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obtained using the same ELISA protocol (R&D Systems, Minneapolis, MN). In addition, 
concentrations of pruritic markers, brain-derived neurotrophic factor (BDNF) and 
substance P (SP), were also investigated before and after treatment. This was achieved by 
another 2 ELISA assays (R&D Systems, Minneapolis, MN; Sigma-Aldrich, Saint Louis, 
Missouri). 
The study also took colonization of Staphylococcus aureus {S. aureus) into 
consideration in order to look for any correlation between the degrees of bacterial 
colonization and AD severity. Swabs (COPAN innovation, Italy) were taken from the 
patients' anterior nares, flexures (anterior neck, antecubital fossae and popliteal fossae) 
and the worst inflammatory skin areas (defined as lesional skin with oozing or crusting), 
with 5 seconds of rubbing in each region. Bacterial cultures of the swab samples were 
carried out by standard laboratory techniques and the sensitivity of any bacterium 
towards commonly used antibiotics were examined (Department of Microbiology, the 
Chinese University of Hong Kong). Bacterial growth was classified as scanty (<10"^  
colony-forming units per mL), moderate (lOMo，)，or heavy (>10^). We defined 
moderate-to heavy growth as significant growth, and scanty or nil growth as negative. 
The results on SCORAD and laboratory parameters in paired samples before and 
after Pentaherbs use were compared using the Paired-samples t tests by SPSS 13.0. The 
correlations between SCORAD and inflammatory markers were analyzed by Pearson 
correlation coefficients. All comparisons were two-tailed, and p values less than 0.05 
were considered significant. 
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3.3 Application of Digitrac in a trial of 0.1% tacrolimus ointment in treatment of 
atopic dermatitis 
3.3.1 Topical imm unomod iilators as a treatment approach of AD 
Another new therapeutic alternative of AD under rapid development over the past 
decade is the non-steroid immunosuppressive drugs, or topical immunomodulators 
(TIMs). They were originally being used as transplantation medicine. FK506 was the first 
one being used in treating dermatological conditions. It is a 822 kDa macrolide lactone, 
which is unstable in aqueous solution and has another name in this form: tacrolimus 
(Nghiem et al., 2002) (Figure 3.8). It is a short polypeptide produced by Slreptomyces 
tskubaensis. Tacrolimus has its greatest penetration power upon inflamed skin sites 
(Ruzicka et al., 1997), and is shown to have a three times greater affinity towards 
cytoplasmic immunophilin FK-binding protein (FKBP) than another common TIM, 
pimecrolimus (Reilamo et al., 2002). 
3.3.2 Mechanism of tacrolimus in suppressing AD and pruritus 
In the immunological pathway of T-cells, calcineurin is a calcium-activated 
phosphatase enzyme responsible for dephosphorylation of the nuclear factor for activated 
T-cells (NF-AT). NF-AT is important in promoting transcription and differentiation of T-
cells into ThI or Th2 types (Novak et al., 2005). Tacrolimus exhibits an inhibitory 
mechanism on the enzyme calcineurin by binding it with a complex of tacrolimus-
FKBP12, calcium and calmodulin (Baldo et al, 2005). After this binding process, the 
transcriptions of NF-AT-dependent genes are turned off, resulting in down-regulation of 
T-cell activities. Therefore, TIMs are also commonly known as calcineurin inhibitors. 
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Tacrolimus has also been found useful in the blockade of inteiieukin-2 transcription 
(Dumont, 2000) and down-regulation of T-cell Fas ligand expression (Shaw et al., 1995), 
thus suppressing immunological responses in patients with AD. 
On the aspect of pruritus, tacrolimus might pose an anti-pruritic effect by its anti-
inflammatory effect because lesional AD skin often shows a dense inflammatory cell 
infiltrates together with an accumulation of neuropeptides that are known to mediate or 
aggravate pruritus (Slander and Luger, 2003;Stander et al, 2003). This is why the side 
effects of pruritus, burning and skin sensations are common in the initial phase of TIM 
treatment (Novak et al., 2005). TIMs are also useful in blocking signal transduction in 
targeting neuronal cells including interleukin-2, which is a known mediator of pruritus, 
thus reducing the sensation of pruritus (Hanifin et al, 2001 ;Rigopoulos et al., 
2004;Stander and Steinhoff, 2002). However, several tacrolimus clinical trials showed 
that mild pruritus is one of the adverse effects of the medication (Bekersky et al, 
2001;Paller et al.’ 2001), yet the occurrence of this symptom would decrease after the 
first few days of the treatment. Based on such a controversy, the Digitrac monitor was 
applied at this stage to objectively measure pruritus and the scratching behavior in AD 
patients upon application of tacrolimus, thus evaluating the feasibility of using such 
medication in relieving itch. 
3.3.3 Study plan 
The study was a case series and no controls were recruited. Emphasis is put on the 
use of Digitrac technique to detect the efficacy of tacrolimus ointment in alleviating 
pruritus and sleep loss in AD patients. The study was carried out in the Department of 
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Paediatrics of The Chinese University of Hong Kong. Written consents were obtained 
from parents for both the use of 0.1% tacrolimus ointment (Fujisawa Healthcare, NY) 
(Figure 3.9) and Digitrac during the treatment. AD patients, aged 2 to 18 years, from the 
outpatient clinic of the Department were recruited for the pilot study. AD was diagnosed 
according to criteria proposed by Hanifin and Rajka (Hanifin and Rajka, 1980). The 
clinical severity of AD was evaluated according to the SCORAD score. All subjects had 
an objective SCORAD > 15 at the entry into this study. Among them, those who had 
active concurrent disease (except allergic diseases such as asthma and allergic rhinitis), 
received psoralen UVA treatment within 8 weeks prior to the study or were allergic to 
calcineurin inhibitors were excluded. 
Participants who fulfilled the above criteria underwent a 1-week run-in period, 
during which their baseline dietary intake, emollient and drug use as well as information 
regarding their severity of AD were collected. Additional medications including their 
usual applications of topical CS or oral antihistamines were not permitted during the run-
in and treatment period. They were then started on topical tacrolimus ointment twice 
daily on affected areas for 2 consecutive weeks. The clinical severity of AD was assessed 
with the SCORAD before run-in, at baseline level and the end of the treatment. The 
patients' and parents'/guardians' assessments of pruritus were also evaluated daily 
throughout the whole study period in the form of a written diary, with a visual analogue 
scale of 0 to 10, with 0 meaning "no-itch" and 10 meaning "worst itch imaginable". 
Nocturnal scratching of the subjects in both groups was evaluated by the Digitrac monitor 
at the first three consecutive days of baseline (days 8 to 10) and at three consecutive days 
after the 2-week, treatment period (days 22 to 24). The purpose of this 'consecutive-day 
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measurement' was to ensure the reproducibility of data. Levels of TARC, CTACK, 
BDNF and SP were also detected using the previous ELISA techniques (Appendix II). 
The degree of adherence to our study regimen was evaluated by weighing the 
amount of 'drugs' that remained in drug tubes, as well as additional drug usage as 
recorded by the patients (if any or due to severe exacerbation of the disease) and sleep 
disturbance in their Eczema Diary. Paired data on SCORAD, Digitrac data and laboratory 
marker levels before and after tacrolimus were analyzed two-tailed by Wilcoxon signed 
ranks test. P-values of less than 0.05 were considered to be significant. 
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3.4 Further application of Digitrac in pruritus of other medical fields 
Pruritus is a common presenting complaint in many diseases other than AD 
(Gabriel and Crone, 2001). Therefore, this part of our study aimed to take a step forward 
in measuring nocturnal pruritus in non-atopic patients by recording their scratching 
behavior with Digitrac. 
In particular, the study came across a 21-year-old pregnant woman presented with 
an itchy generalized bullous eruption with no past history of atopy or skin dryness 
(Figures 3.10 and 3.11). At week 19 of gestation, she developed an itchy rash over the 
limbs, which spread to the trunk. Blisters then appeared on the hands which subsequently 
also involved the feet. There were no fever, oral or genital lesions and she denied the use 
of over-the-counter or herbal medicine. Continuous pruritus and sleep loss due to the skin 
condition was reported by the patient. 
On examination, she had multiple erythematous patches and plaques over the 
trunk and limbs. Bullae were seen on limbs, particularly on hands and feet. 
Ultrasonographic assessment revealed a single live fetus with normal anthropometric 
parameters and normal volume of amniotic fluid. A skin biopsy was performed (by the 
Dermatology Research Centre, The Chinese University of Hong Kong), which showed 
palmoplantar skin with eosinophilic spongiosis with superficial and mid interstitial 
inflammatory and eosinophilic infiltrates. Immunofluorescence study showed moderate 
staining for complement-S (C3) at dermoepidermal junction. The collection of 
eosinophils at papillary dermis attempting to form subepidermal blister and the strong 
immunofluorescein stain for C3 favored the diagnosis of pemphigoid gestationis (PG). 
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The nocturnal scratching pattern was documented with the Digitrac wrist monitor 
on the day which the patient reported the most intense pruritis since her admission to the 
hospital. The wrist activities of a normal person and that of a patient with severe eczema 
were measured as reference. 
Another rare case under my study of pruritus was a previously healthy 3-year-old 
girl who presented with a recent onset of generalized itch over her genitalia without rash 
in May 2005. She was treated as vulvo-vaginitis by a local general practitioner. There 
was no improvement in her symptoms, and itchiness worsened to affect the whole body. 
She was then treated as scabies by another doctor at that moment because there were red 
spots at the fingers. This little patient was then treated as eczema upon the consultation 
by another dermatologist, even though she and her family had no atopies and her skin did 
not show any typical pattern of skin involvement for AD. Treatment with various 
antihistamines including certirizine did not improve her skin condition. She subsequently 
developed antalgic gait with right hip pain (for 10 days) and persistent fever with cough 
and running nose a month later. The range of movement of her right hip was found to be 
decreased, and subsequent X-ray showed multiple osteolytic lesions with pathological 
fracture at right femur neck. Further imaging showed lesions involving right skull, right 
anterior fourth rib and left sacrum. Bone biopsy was performed in late June 2005, which 
showed small bone cell tumor with pathological fracture. Trephine examination 
performed a week later revealed abnormal lymphoid infiltration with medium to large 
lymphoid cells showing irregular nuclei and infiltration of small T-lymphocytes. The 
diagnosis of peripheral T-cell lymphoma was finally made with further radiological and 
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histopathologica丨 investigations，with persisting itch over right femur and complaint of 
nocturnal pruritus, affecting her sleep. 
Despite the severe itch, onycolysis of the left index fingernail in this patient only 
showed minimal scratch marks on her right gluteal region with no flexural involvement. 
To further look at the intensities and extent of pruritus in such a rare disease, itch pattern 
prior to and following chemotherapy were documented by the Digitrac movement 
monitor. The results obtained were compared with nocturnal wrist movements of a 
normal subject and a child with severe AD. 
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Figure 3.1 Digitrac® movement recorder (IM Systems, Baltimore, MD) 
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• • 
Figure 3.2 Digitrac3.9, A program facilitating downloading data stored inside Digitrac to 
computer for analysis (IM Systems, Baltimore, MD). 
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SCORAD [NSTITLTION 
I EUROPEAN TASK FORCE ； 
ON ATOPIC DERMATITIS PHYSICIAN 
(for children under 2 years) 
Topical Steroid used Name: 
Name: Date of Birth: 
Amount/Month: (G) Date of Vis it: 
Number of flares / Month: 
. 5 
m-ji i/Lm 
I lAl' Lm _ I 
A: EXTENT Please indicate the area involved 
B: IfSTEMSITY I CRITERIA | INTENSITY MHANS QF CAI.ATION 
INTENSITY ITEMS 
Edema/Papulation (average representative area) 
Oozing/Crust 。= absence 
Excoriation l，mild 
Lichetiification 2-inoderate 
D n m w s * 3=severe 
• Dryness is evaluated on uninvolved areas 
C: SUBJECTIVE S Y M P T O M S P R U R I T U S t SLEEP LOSS 
Visual analog scale p j ^ ^ j ^ ^ ^ g (0 to 10) 
(average for the last 0 10 
3 days or nights) SLEEP LOSS (0 to 10) ； 
S C O R A D A/5 + 7Bn + C TREATMENT: 
R E M A R K S : 
Figure 3.3 The SCORing Atopic Dermatitis index (SCORAD) diagnosis worksheet (1993) 
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a) 
b) 
Figure 3.4 Evaluation of Laboratory markers of AD and pruritus using enzyme-linked 
immunosorbent assay (ELISA) techniques. 
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1 姓名•• 
1 後« ： ^ 年 ： 厂 
I *日2次/每次3粗 
»-、. ： . _ ^ ^ 工 一 __ ^ 
Figure 3.5 Pentaherbs capsule. Patients were instructed to take 3 capsules twice daily. 
Capsules were considered to eliminate the taste of bitterness of traditional Chinese herbs. 
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CHILDREN'S DERMATOLOGY LIFE QUALITY INDEX 
Hospital No: 
Name: Diagnosis: CDLQI 
Age： S C O R E： 
Address： Date: 
The aim of tills questionnaire is to measure how much your skin problem has 
affected you OVER THE LAST WEEK. Please tick • one box for each question. 
1. Over the last week, how itchy, "scratchy", Very much • 
sore or painful has your skin been? Quite a lot • 
Only a little • 
Not at all • 
2. Over the last week, how embarrassed Very much O 
or self conscious , upset or sad have you Quite a lot • 
been because of your skin? Only a Little • 
Not at all • 
3. Over the last week, how much has your Very much • 
skill affected your friendships? Quite a lot • 
Only a little • 
Not at all • 
4. Over the last week, how much have you changed Very much • 
or worn different or special c lothes / shoes Quite a lot • 
because of your skin? Oiily a Little • 
Not. at all • 
5. Over the last week, how much has your Very much • 
skin trouble affected going out, playing. Quite a lot • 
or doing hobbies? Only a little • 
Not at all • 
6. Over the last week, how much have you Very much • 
avoided swimming or other sports because Quite a lot • 
of your skin trouble? Only a little • 
Not at all • 
7. Last week. — If school time： Over the Prevented school • 
was It z last week, how much did Very much • 
school t ime? z your skin affect your Quite a lot • 
school work? Only a little • 
OR Not at all • 
was It — If holiday time： How much Very much • 
holiday t ime? ^ over the last week, has your Quite a lot • 
skin problem Interfered with Only a little • 
your enjoyment of the holiday? Not at all • 
8. Over the last week, how much trouble Very much • 
have you had because of your skin with Quite a lot • 
other people calling you names, teasing, Only a little • 
bullying, asking questions or avoiding you? Not at all • 
9. Over the last week, how much has your sleep Very much • 
been affected by your skin problem? Quite a lot n 
Only a little • 
Not at aU • 
10. Over the last week, how much of a Very much • 
problem has the treatment for your Quite a lot • 
skin been? Only a little • 
Not at all • 
Please check that you have answered EVERY question. Thank you. 
®M.S. I-ewta-JonKa. A.Y. KUilay, May 1993. Thla must not be copied without thr permission of the auUiora. 
Figure 3.6 The Children's Dermatology Life Quality Index (CDLQI) (Lewis-Jones and 
Finlay, 1995) 
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兒童皮商科生活質素指數 
呢份問卷調査哦目的fi度過去一個星期甚面’你嚼皮庙問題對你生活概影银有幾大》請你略每 
—條問題哦其中_個空格S—個副號» 
1.临過去一個星期裘面’你哦皮《痕、瘦、酸痛或者痛哦程度點樣 非常嚴重 
呢？ 嚴 重 口 
些少 • 
無 • 
2.晩過去一個星期裏面’你因爲皮麻問題而產生抵拉、太注意自己、 非常嚴重 • 
唔開心或者傷心哦程度點樣呢？ 厳重 • 
些少 • 
無 • 
3.晚、過去一個星期裏面，你哦皮庙問題對你同朋友之間槪關係影有 非常嚴重 • 
幾大？ 嚴重 • 
些少 • 
無 • 
4.临過去一個星期褢面’你截皮商問題令你換衫/鞋或者着特別嘲衫 非常多 • 
/鞋多唔多呢？ 多 • 
些少 • 
無 • 
5.晩過去一個星期褒面•你哦皮膚問題對你出街、玩或者做你鐘意做 非常嚴重 • 
哦嚼哦影》有幾大？ 厳重 • 
些少 • 
無 • 
6.啦過去一個星期褢面’你因爲皮《問題而要避免游水或者做其他運 非常多 • 
動哦情況多唔多？ 多 • 
\ 些 少 • 
\ 無 • 
7. IMM' 如果係返學時間：临過去一個星期裘 不能上課 • 
mom 面 I你赃問題對你哦學業有幾大影 非 常 雌 • 
返學時間 趣？ •嚴重、 • 
些少 • 
或者 無 • 
係唔係 如果係假期：喉過去一個星期琪面•你 非常厳重 • 
mm 礙你享受假期有幾厳重？ MM • 
些少 • 
無 • 
8.晚過去一個翻裏面•你因爲颇問題而俾人叫花名、笑、 非常多 • 
「瑕J、問問題或者避開你’ n甘概麻煩多唔多呢？ 多 • 
些少 口 
無 • 
9. Bi過去一個US裹面’你哦_問題影趣你獄覺多唔多呢？ rf常多 • 
多 • 
些少 • 
無 • 
10.临過去一個M裏面•皮/！^^理帶俾你暇問題有幾大？ 非常嚴重 • 
厳重 • 
些少 • 
無 • 
講你檢査你係唔係已經答晒所有問題•多謝。 
®M.S. Lewis-Jones, A.Y. Finlay, May 1993 
Figure 3.7 The Cantonese-translated version of the CDLQl (Chuh, 2003) 
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Figure 3.8 Structure of tacrolimus. The CAS Registry name of tacrolimus is as follows: 
[3S-[3R*[E(1S*, 3S*，4S*)], 4S*, 5R*, 8S*, 9E, 12R*，14R*, 15S*，16R*，18S*，19S*, 
26aR*]]-5，6，8，11’ 12, 13’ 14，15，16，17，18，19, 24, 25, 26, 26a-hexadecahydro-5, 19-
dihydroxy-3-[2-(4-hydroxy-3-methoxycyclohexyl)-l-niethylethenyl]-14,16-dimethoxy 
4,10,12,18-tetramethyI-8-(2-propenyl)-15,19-epoxy-3H-pyrido[2, l-c][l ,4] 
oxaazacyclotricosine-1,7,20,21 (4H,23H)-tetrone, monohydrate. The empirical formula of 
tacrolimus is C44H69N012H20; formula weight is 822.05 daltons. 
H H ^ H f m 
i P f o t o p i ^ _ 狐 ^ 
I 
Figure 3.9 Tacrolimus ointment 
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Figure 3.10 Wide spread bullous lesions with erythematous base found on the trunk on 
the patient suffering from pemphigoid gestationis. 
• 
Figure 3.11 Hemorrhagic bullae on the palm of the patient suffering from pemphigoid 
gestationis. 
51 
Chapter 4 
Results and Discussions 
4.1 Digitrac validation 
4.1.1 General demographic background data 
43 patients (24 males, 19 females) and 37 healthy controls (14 males, 13 females) 
with no atopy history were recruited for the validation of Digitrac during the period 
August 2004 to August 2005. The mean (standard deviation) age for patients and controls 
was 11.9 (3.6) years and 11.9 (3.4) years, respectively (p=0.975). The mean (standard 
error of mean, SEM) SCORAD in the group of AD patients was 49.0 (3.43). All subjects 
were enrolled into study with a SCORAD score of >15. The controls had either trivial 
skin diseases (2 with acne, 1 with alopecia totalis, and 1 with dandruff) or were normal 
healthy children of the clinic staff. 
The mean (SEM) serum total IgE level and eosinophil percentage in PB were 
5844 (1293) klU ml'' and 8.4 (0.8) %，respectively. As both means are higher than the 
suggested reference value of 180 klU ml'' and 6%, the patients showed signs of atopy. 
Although SCORAD was the gold standard used in this study, it did not contain a 
severity grading and the scoring of scratching and sleep disturbance lacked objectivity 
and were difficult to be studied. Since the main objective is to validate the objectiveness 
of the device, a score of objective SCORAD, i.e. the total SCORAD score minus 
subjective pruritus and sleep loss scores reported by parents, was also included in 
statistical analysis during device validation. The objective SCORAD score has rid on 
subjective symptoms and provides a severity grading, with score < 15 considered to be 
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mild, 15 < score $ 40 to be moderate, and > 40 to be defined as severe AD (Kunz et al., 
1997). 
It was hypothesized that the patients would find themselves difficult to get asleep 
at the early hours after getting to bed. Therefore, this study focused on the first few hours 
of sleep for the first part of validation. To define the beginning of sleep, the patients are 
required to give a verbal report of the time they got to bed. When visually observed and 
compared with controls with the aid of the computer program, most wrist activities in 
both groups occurred in the first three hours of bed resting (Figure 4.1). The average 
wrist activities in the early hours of sleep of both patients and controls were shown in 
table 4.1. Activities of individual hour within the first three hours of sleep of AD patients 
showed significant difference with that of the controls, after performing Wilcoxon sign-
ranked test, with p<0.01 (Table 4.1). 
4.1.2 Wrist activities 
By performing Pearson parametric correlations, the average wrist activities of the 
second and third hour of sleep correlated well with overall and objective SCORAD 
(/7=0.001 for second hour, p<0.001 for third hour of sleep) (Table 4.3). Similar 
correlations were also observed for the average value for the first three hours of sleep 
(/7<0.001), yet could not be found in the first hour. There were also significant 
correlations between average activities and component scores of SCORAD (Table 4.3), 
with the highest correlation of p=0.590 and =0.551, p < 0.001 for overall extent and 
intensity, respectively. However, there was no correlation with pruritus score within the 
SCORAD, which was subjectively reported by the patients or their parents. 
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The frequencies of limb motions during early hours of sleep were also recorded 
by the device during validation. Wrist activities at frequencies of 0 to 3 hertz (Hz, or 
cycles per second) consisted of the largest portion of activities (Figure 4.2 and Table 4.2), 
suggesting the nature of wrist movements of the group of AD patients in this study were 
of small amplitude. By performing Pearson parametric correlations, all frequency-
specific wrist activities at 0-1 Hz, 1-2 Hz, 2-3 Hz and a total of 0-3 Hz correlated well 
with total and objective SCORAD (p=0.005, 0.001, 0.001 and 0.002 for SCORAD, 0.004, 
0.001, 0.002 and 0.002 for objective SCORAD, respectively) (Table 4.4). Similar to 
average activity, there were no correlations between Hz-specific wrist activities and 
pruritus score. 
4.1.3 Laboratory markers and factor analysis 
The mean (SEM) levels of TARC and CTACK were 760 (180) and 688 (119) 
pg/ml, respectively. TARC revealed a strong correlation with Digitrac findings, after 
performing Pearson correlation test (Table 4.5). Wrist activities of the second hour, third 
hour and an average of 0-3 hour of sleep correlated well with plasma TARC 
concentrations, but not with CTACK. Such a correlation could not be found for the data 
during the first hour of sleep. Frequency-specific wrist activities also showed sounding 
correlations with TARC levels. 
When the interdependence among subjective and objective severity scores, 
Digitrac readings and laboratory parameters were assessed for factor analysis, Baiiett's 
test of sphericity indicated a correlation between these variables because the correlation 
matrix was statistically different from an identity matrix (x" = 366.82, degree of freedom 
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= 2 8 , /kO.OOOOI) (Table 4 . 6 ) . The Kaiser-Meyer-Olkin measure of sampling adequacy 
was 0.630, which was above minimum acceptable value, indicating that the data was 
likely to factor well. Factor analysis yielded four factors that could explain 81.37% of the 
total variance in the data set (Table 4.6). In brief, the objective indicators (SCORAD, 
objective SCORAD and related components within), self-reported scores (subjective 
components of SCORAD including pruritus and sleep loss), Digitrac findings and 
objective laboratory markers (Plasma IgE concentrations and total white cell count) were 
separate domains during assessment of AD in the validation study, indicating their 
independent importance for interpretation of data. 
4.1.4 Interpretation of results 
Wrist movements did not correlate with the subjective symptoms of pruritus. 
Previous studies documented that the subjective symptoms were not necessarily 
correlated with the objective index of disease severity of AD in patients (Hon et al” 
2003). This validation study further speculated that it is either the subjective symptoms of 
pruritus reported by parents are imprecise, or mechanisms other than disease extent or 
severity, that is responsible for the pathogenesis of these symptoms. As previously 
reported, it is common for children in Hong Kong to be looked after by a maid and 
therefore parents may not know or witness their child's condition at night. Some older 
children may have their own room and therefore the quality of their sleep is not witnessed. 
Possible alternative explanation is that pruritus may be due to mechanism other than the 
extent and intensity of skin inflammation. Scratching and sleep disturbance has been 
difficult to study (Rees and Laid law, 1999). Some scoring systems, therefore, have 
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bypassed these assessments and adopted a more objective approach. The typical example 
is the objective SCORAD, an index without the pruritus and sleep-loss components. 
However, itch and scratching should never be neglected, and are important parameters to 
be assessed objectively in order (i) to document the amount of disability or impairment of 
quality of life caused by the disease as well as (ii) to gauge therapeutic efficacy of 
alternative, expensive or potentially harmful treatment. Therefore the validation of 
Digitrac might provide an alternative for measuring these important clinical parameters. 
AD is a very common disease in children and is studied at various levels by 
physicians. For instance, when referring to pruritus and sleep quality, general 
practitioners or paediatricians might be interested in linking up with the quality of life of 
children with AD. Dermatologists, on the other hand, may be interested in the advances 
in therapeutics and specific clinical scores, whereas immunologists may be interested in 
chemokine responses instead. Assessment of wrist movements appears to be an 
inexpensive and noninvasive methodology that generates easy-to-comprehend data which 
are correlated all around, and hence provide a platform, for linking up various markers 
and scores. 
It is important to ask the fundamental question as to what is more important to 
measure, itch or scratching? Although unbearable to the sufferer at times, the sensation or 
feeling of itch might or might not be totally translated to scratching and restless wrist 
movements. Itch by itself does not lead to further damage or inflammation. Yet as 
previously discussed, itch and scratch were two interdependent parameters and 
researchers have proven strong correlations among pruritus and sleep loss. 
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It is also important to understand what is being measured when one measures AD. 
Scratching is important in the pathogenesis of AD, causing further breakage of skin 
barrier and release of inflammatory cytokines. Various studies recently reported a 
significant correlation between serum CTACK concentration and overall SCORAD 
( P = 0 . 3 9 4 , / 7 = 0 . 0 1 6 ) and its extent (p=0.528，；;=0.001) and intensity components (p=0.429， 
/7=0.008); but not with subjective symptoms of sleep loss and pruritus (Hon et al., 2004a). 
All these suggested that measurements of objective laboratory markers are useful to have 
a more complete look at the actual picture of pathogenesis of pruritus and wrist 
movements. It is therefore not surprising that our study demonstrates a significant 
correlation between TARC and wrist movements rather than itch. Our findings concur 
with the observation that TARC, being a key immunological marker, correlates with 
objective signs (extent and intensity) but not subjective features (pruritus) of AD. Wrist 
movements, but not the subjective symptom of itch, do appear to have an immunological 
basis in terms of pathogenesis. 
To date, there has been no perfect gold standard for assessing AD severity. Worse 
still, there has been no objective gold standard for assessing the inter-relationship 
between pruritus and sleep loss in children. It has been found out that total sleep 
efficiency was lower in patients with severe AD than that obtained in the control (median: 
72% versus 88%; p = 0.039) (Hon et al, 2005b). However, measurement of sleep 
efficiency was cumbersome and required hospitalization for overnight assessment. Other 
investigators have suggested that wrist movements were also correlated with sleep 
efficiency and accelerometer device might be an option to be used at patient's own home 
(Benjamin et al., 2004). Quantifying new markers and correlating their levels with 
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clinical scores may provide better understanding of AD and facilitate researches to 
improve its management. 
4.1.5 Drawbacks of the validation 
There are several limitations in this study. Firstly, only the nocturnal wrist 
movements of the dominant hand were recorded. Ideally, limb movements of all four 
limbs should be recorded. As correlations for movements in various limbs are good 
according to other studies, they also suggest that little information would be lost if only 
one limb was measured. 
Another important ambiguity that should not be neglected is that the recorded 
limb movements might not be solely due to scratching. It could be non-specific restless 
movements, which could not be delineated without video analysis (Benjamin et al., 2004). 
Benjamin et al., using the ActiGraph, demonstrated that scratching and restless 
movements were highly correlated with each other and with video results. They also 
pointed out that little is gained to delineate these movements one from the other. It may 
be that the subjective feeling of itch leads to both purposeful scratching activities and 
purposeless restless movements. The validation study this time therefore did not assess 
individual movements but evaluated the frequencies and timing of assessment of these 
movements instead. Based on the fact that wrist activities were concentrated on low-
frequency bandwidth, other non-specific movements that fall out of the range were 
further excluded for study. Further, the study demonstrates that only very little 
movements, be it scratching or restless movements, occur in normal control subjects with 
a very strong basis of significant difference from AD subjects. Therefore, a large portion 
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of wrist movements are AD-associated, and is not necessary to segregate one form of 
movements from the other for the purpose of analysis. 
Lastly, we did not monitor the wrist movements for longer period, which might 
cause a "first-night effect" leading to inaccuracies of the measurement. In the later part of 
the study, continuous measurements were performed to counteract with this shortcoming. 
4.1.6 Summary 
To summarize, wrist movement is easy to be documented non-invasively at the 
patient's own home, which is the most comfortable and appropriate environment for 
validation study. Its clinical nature and basis is objective and correlated with clinical 
laboratory markers of eczema severity. Although wrist movement monitoring is not going 
to replace clinical or biochemical assessment, it offers supplementary objective data to 
the understanding of the complex itch-scratch cycle in children with AD and thus worth 
further explorations and applications in various clinical trials. From the above results, 
wrist activities between 0 and 3 Hz for first three hours of sleep might become a useful 
non-invasive home-based objective indicator of sleep disturbance and eczema severity in 
children. The findings that wrist activities were correlated with wrist movements were 
consistent with the findings reported with various studies using accelerometer devices 
(Benjamin et al, 2004). In addition, with reference to the relationship between wrist 
activities, pruritus and slower movements ( 0 - 3 Hz) and related laboratory markers, the 
validation accurately documented that it is the occurrence of these movements during 
early sleep rather than itching that are T-helper-2 chemokine mediated. 
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Figure 4.1 Visualizations of wrist activities during sleeping in (a) a normal subject versus 
(b) a patient with severe atopic dermatitis with the aid of Digitrac 3.9 (IM Systems, 
Baltimore, MD). Data were expressed in units of g min"^  within each individual hour. 
Most wrist activities occurred in the first three hours during sleep. 
60 
a) 
40 mg -
11:00 P , � 
11:10 P M \ . 、 \ 
\ Average Spectrum 
1 1 : 2 0 P M V I 、、 ’‘ \ \ 上 
11:30 P H J \ ^ 、 \ 「 、 \ \ 
\ \ \ \ 0 
11:40 P M \ , \ 0. 2. 4. 6. 8. 10. 
\ \ \ \ \ 
11:50 P M \ \ \ 
1 1 T — 1 1 
0. 2. 4. 6. 8. 10. 
Frequency 
b) 
40 mg-ll 
11:00 . 
脾 《 丨 V . 
11 :io P M ^ i M r i ， 兮 ， ¥ 
^ 一 2 0 , Average Spectrum 
• ^ ^ ^ i ^ ^ i t e ^ ， ^^  I 
11:40 PMa^ i I " \ 0. 2. 4. B. 8. 10. 
11:50 ；广：： 一 
V-^ r > 1 1 » 
0. 2. 4, 6. 8. 10. 
Frequency 
Figure 4.2 Typical changes in frequencies of wrist activities in a) a normal control, versus 
b) a child with severe atopic dermatitis in the early zero-to-three hours of sleep. Most 
activities occurred in the frequency bandwidth 0-3 Hz. 
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1st hour 2nd hour 3rd hour 4th hour 5th hour 6th hour 7th hour 8th hour 
Hours After Getting in Bed 
/7-value 0.154 0.001** <0.001** 0.172 0.069 0.500 0.217 0.740 
Figure 4.3 Mean wrist activities (g min' ') over time for consecutive 8 hours of sleep for 
children with severe atopic dermatitis (n=43) versus controls (n=37). By performing 
Pearson correlations with SCORAD, significant results were obtained at second hour, 
third hour and average values from 0-3 hour of sleep. As a result, analysis onwards was 
based on findings during early hours of sleep. 
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Mean (SEM) First Second Third Average 
wrist activity (g min'') hour hour hour 0-3 hour 
AD patients ( n = 4 3 ) 1 2 3 . 6 * * 9 7 . 8 * * 118.9** 113.4** 
(13.6) (12.3) (16.4) (10.2) 
Controls (n=37) 33.0 32.2 37.8 34.1 
(1.6) (1.4) (2.2) (1.2) 
** p<0.01 ； 2-tailed. 
Table 4.1 Mean wrist activity for AD patients and controls (g min''). Difference among 2 
groups was significant for every single hour over 0-3 hour. 
Mean (SEM) 0-1 Hz 0-2 Hz 0-3Hz T ^ “ 
Hz-specific wrist activity (mg min"') 0-3 Hz 
AD pa t i en t7 (n="^ )一2^76 m A ~665To 
(29.9) (22.5) (17.0) (67.7) 
Table 4.2 Frequency-specific mean wrist activity of AD patients for the first three hours 
of sleep (mg min"'). 
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First Second Third Average 
Average wrist activity hour of hour of hour of 0-3 
(g min"') (n=43) sleep sleep sleep hours 
SCORAD Pearson p 0.221 .473(**) .521(**) .569(**) 
p 0.154 .001 .000 .000 
Objective 0.206 .502(**) .521(**) .574(**) 
SCORAD 0.186 .001 .000 .000 
Extent 0.177 .519(**) .562(**) .590(**) 
0.257 .000 .000 .000 
Intensity 0.207 .482(**) .493(**) .551(**) 
0.183 .001 .001 .000 
Erythema 0.154 .506(**) .464(**) .522(**) 
0.324 .001 .002 .000 
Edema / 0.170 .403(**) .456(**) .483(**) 
Papulation 0.277 .007 .002 .001 
Oozing / 0.290 .161 .311(*) .361(*) 
Crusting 0.060 .302 .043 .018 
Excoriation 0.249 .254 .443(**) .451(**) 
0.107 .100 .003 .002 
Lichenification 0.037 .463(**) .423(**) .430(**) 
0.813 .002 .005 .004 
Dryness 0.088 .462(**) .245 .357(*) 
0.574 .002 .114 .019 
Subjective score 0.217 .218 .366(*) .381(*) 
0.163 .159 .016 .012 
Pruritus 0.115 .183 .314(*) .294 
0.461 .240 .040 .056 
Sleep loss 0.270 .218 .359(*) .401(**) 
0.080 .160 .018 .008 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
Table 4.3 Correlations of Digitrac findings of average wrist activity (g min"') with 
SCORAD, objective SCORAD and related component scores. All data were expressed in 
Pearson's p followed by a 2-tailed p-value and so on. 
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Frequency-specific 0-1 Hz of 1-2 Hz 2-3 Hz Total 
Average wrist activity limb of limb of limb 0-3 Hz 
(mg mill"') (11=43) motions motions motions 
SCORAD Pearson p 0.419** 0.485** 0.473** 0.465** 
p 0.005 0.001 0.001 0.002 
Objective 0.427** 0.474** 0.461** 0.462** 
SCORAD 0.004 0.001 0.002 0.002 
Extent 0.436** 0.492** 0.473** 0.475** 
0.003 0.001 0.001 0.001 
Intensity 0.415** 0.456** 0.446** 0.446** 
0.006 .002 0.003 0.003 
Erythema 0.425** 0.421** 0.394** 0.426** 
0.004 0.005 0.009 0.004 
Edema / 0.327* 0.373* 0.384* 0.365* 
Papulation 0.032 0.014 0.011 0.016 
Oozing / 0.318* 0.391** 0.368* 0.363* 
Crusting 0.037 0.010 0.015 0.017 
Excoriation 0.269 0.326* 0.328* 0.309* 
0.081 0.033 0.032 0.044 
Lichenification 0.308* 0.322* 0.334* 0.327* 
0.044 0.035 0.029 0.032 
Dryness 0.289 0.309* 0.290 0.303* 
0.060 0.044 0.059 0.048 
Subjective score 0.262 0.384* 0.381* 0.339* 
0.090 0.011 0.012 0.026 
Pruritus 0.157 0.249 0.249 0.214 
0.316 0.108 0.108 0.168 
Sleep loss 0.313* 0.442** 0.437** 0.395** 
0.041 0.003 0.003 0.009 
** Correlation is significant at the 0.01 level (2-tailed). 
* Correlation is significant at the 0.05 level (2-tailed). 
Table 4.4 Correlations of Digitrac findings of frequency-specific average wrist activity 
(mg min"') with SCORAD, objective SCORAD and related component scores. All data 
were expressed in Pearson's p followed by a 2-tailed ;?-valiie. 
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Factor 1 Factor 2 Factor 3 Factor 4 
SCORAD 0.783 0.421 0.282 0.350 
Objective SCORAD 0.852 0.281 0.285 0.327 
Extent 0.772 0.358 0.294 0.288 
Intensity 0.859 0.242 0.273 0.335 
Erythema 0.831 0.207 0.224 0.027 
Edema/Papulation 0.700 0.133 0.247 0.534 
Oozing/Crusting 0.231 0.189 0.430 0.575 
Excoriation 0.680 0.145 0.202 0.460 
Lichenification 0.820 0.078 0.172 0.068 
Dryness 0.814 0.373 0.010 -0.016 
Subjective Score 0.266 0.864 0.188 0.339 
Pruritus 0.400 0.753 0.037 0.295 
Sleep 0.120 0.838 0.286 0.330 
Average wrist activity for 
0-3 hours of sleep 0.342 0.141 0.887 0.010 
0-3Hz-specigic activity for 
0-3 hours of sleep 0.206 0.152 0.928 -0.022 
Plasma IgE concentration 0.434 0.301 -0.023 0.619 
Periphem! blood o.499 0.590 0.050 -0.212 
eosinophil count 
Total blood 0.024 0.141 -0.111 0.639 
White cell count 
—Eigenv^ ^ ^22 2.47 2.41 
Total variance explained, % 36.37 17.91 13.74 13.37 
Table 4.6 Varimax rotated factor-loading matrix for all 43 AD patients. Bold values 
represent the highest factor loadings. The objective indicators (SCORAD, objective 
SCORAD and related components within), self-reported scores (subjective components 
of SCORAD including pruritus and sleep loss), Digitrac findings and objective laboratory 
markers (Plasma IgE concentrations and total white cell count) were separate domains 
during assessment of AD in the validation study, indicating their independent importance 
for interpretation of data. 
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4.2 Digitrac in traditional Chinese herbal medication clinical trial 
4.2,1 General information 
28 have completed the whole TCM course with Digitrac monitoring and provided 
adequate data for analysis, None of them violated the patient selection criteria. All 
subjects complied well with the instructions given on consuming the medication, without 
difficulties for capsule swallowing or any other severe adverse effects or acute 
exacerbation of eczema according to the returned eczema diary. For the device, all 
patients followed instructions clearly for using the device and none of them reported any 
discomfort throughout the process. The patients' starting and ending time of sleep were 
recorded clearly by the parents. Only those wrist movement data collected afterwards 
were considered to be valid. 
To ensure safety, liver and renal function tests have been performed at the 
beginning and at the end of the study. None of the participants showed any abnormality. 
Mean (SEM) serum total IgE, PB eosinophil and total white cell counts before and after 
the 12-week trial medication were 5413 (1391) vs. 4747 (1256) klU ml 8.3 (1.0) vs. 
8.3 (1.0) and 7.1(0.4) vs. 7.8 (0.4) xlO^ L'', respectively. While IgE and eosinophils 
showed a decreasing trend, the difference was not significant after performing paired-
samples t-test. 
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4.2.2 SCORAD, wrist activities and CDLQI 
The mean (SEM) SCORAD scores of the patients before and after trial were 46.2 
(3.4) and 42.4 (3.7) respectively (Table 4.7). Objective SCORAD scores, after excluding 
the subjective scoring, were 36.1 (2.9) and 33.3 (2.9) before and after trial, respectively. 
The difference between both SCORAD and objective SCORAD were not significant. The 
score on sleep loss reported by parents, however, showed statistically significant 
difference among each visit (p=0.042) (Table 4.7). 
All patients (or parents / caregivers, provided if the patient was too young to 
understand the wordings of the questionnaire) were required to fill in the CDLQI 
questionnaire prior to the study, at the baseline of the trial. Minimum instructions were 
given; therefore the CDLQI score would be able to solely represent the subjective 
perception of the impairment of quality of life by the patients or parents themselves, 
without interference from investigators. The mean (SEM) total CDLQI score of the 
patients right before starting of trial was 8.79 (1.01). Correlations of individual question 
scores with subjective symptoms scores within the SCORAD were performed (Table 4.8). 
Subjective scores, including pruritus and sleep loss, correlated well with the total CDLQI 
score (p<0.01) and also scores of the questions related to scratching and sleep loss 
(p<0.05). Such correlations were probably due to the nature of subjectiveness of both 
scoring systems. Similar statistical tests were also performed with baseline readings from 
Digitrac and the data from the device did not correlate significantly with CDLQI 
outcomes, except the average activity with total CDLQI score (p=0.440,/7<0.05). 
Patients were instructed to wear Digitrac on the first day and the last day of the 
study and pre-post Digitrac data were compared using paired t-tests (Figure 4.4). The 
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mean (SEM) wrist activity of the patients over the first 3 hours decreased significantly 
from 113.4 (12.2) g m i n ' to 76.2 (8.1) g min"' before and after TCM trial (p=0.001) 
(Table 4.9a). When taking individual hours into considerations, significant difference was 
also obtained for the second and third hour of sleep of the patients after receiving the 12-
week. TCM medication. Wrist activity of 0-3 Hz within the period also showed significant 
decrease, from 689.4 (84.5) mg min-' to 410.3 (50.0) mg min"' 09=0.002) (Table 4.9b). 
For ensuring reproducibility of results from previous validation, the whole set of 
Digitrac data in TCM trial were also compared back with the SCORAD and related 
component scores (n=56) (Table 4.10). After performing Pearson correlations, data 
recorded from Digitrac strongly correlated with total SCORAD, objective SCORAD, 
extent and intensity, (p=0.007, 0.005, 0.003 and 0.008，respectively) but not with 
subjectively reported scores of pruritus and sleep loss (p=0.062, 0.079, respectively). 
4.2.3 Laboratory findings 
Swabs were taken obtained from the anterior nares, flexures (anterior neck, 
antecLibital fossae and popliteal fossae) and the worst inflammatory skin areas of the 
patients before and after TCM trial. The most severely affected region from each patient 
during separate visits was taken for statistical analysis. Among the 28 patients, 12 showed 
improvements in Staphylococcus aureus colonization on their most severely affected 
region, 7 subjects deterioration and 9 with no change. The difference was not statistically 
significant, indicating TCM might not be useful in improving AD through elimination of 
S. Aureus. 
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The levels of various laboratory markers before and after TCM trial were obtained 
through ELISA assays. The mean (SEM) levels of the two inflammatory chemokines, 
plasma TARC and CTACK, before and after trial were 824 (189) vs. 492 (101) and 1424 
(136) vs. 1087 (66) pg/ml, respectively. Both levels were significantly decreased 
(p=0.013, 0.020, respectively) (Table 4.11). For pruritic markers, both levels of plasma 
brain-derived neurotrophic factor (BDNF) and substance-P (SP) dropped significantly, 
from 1798 (177) to 1378 (146) for BDNF, and 93.6 (8.0) to 72.9 (6.4) pg mP^ for SP, 
respectively (p=0.002). Pearson correlations of BDNF and SP were done against 
subjective symptom scores of SCORAD and readings from Digitrac (n=56) (Table 4.12). 
The markers correlated very well with the Digitrac data (Pearson p=0.878 and 0.897 for 
BDNF and SP respectively, p<0.00001), but not significantly correlated with the 
subjective report scores from patients or parents. 
4.2.4 Interpretation of results 
The study showed that Pentaherbs capsules apparently improved the severity of 
AD in these patients, yet not significant. The actual therapeutic effects appeared to persist 
along the whole treatment course, yet by referring to SCORAD score, the extent of 
apparent improvement was slow. 
In Chinese medicine, "wind", "dampness" and "heat" are considered to be the 
main pathogenic factors. The five herbs used in the study of this formulation are proposed 
to work as follow: Jingyinhna and Bohe clear wind-heat from the exterior, Danpi clears 
heat from blood, while Cangzhu and Huanghai clear the wind-heat from interior. This 
formula has been extensively used in China for treatment of allergic diseases including 
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eczema, asthma and allergic rhinitis. Pharmacological studies have documented that these 
herbs have anti-allergic, anti-inflammatory and sedative action for itch and they have 
been previously used in the study of childhood AD (Xu et al., 1997;Huang, 1998). 
The actual action mechanism of pruritus improvement of sleep loss or pruritus of 
traditional Chinese medication still leaves a large room for further research. Currently 
only little has been done on related research field, with only one conducted using a TCM 
called Sho-seiryu-to marketed in Japan (Sakaguchi et al., 1997), which claimed to be an 
antihistamine / anti-allergy medication, inhibiting vascular permeability induced by 
histamine and histamine release by mast cells, hence soothing the sensation of pruritus. 
Our study took a step forward by applying devices to monitor improvement in an 
objective manner, thus ensuring the efficacy of medications and providing an insight into 
the mechanism of the drugs in its anti-inflammatory and anti-pruritic roles, basing on the 
significant differences in the laboratory marker levels. In particular, the strong 
correlations of pruritic markers with Digitrac and the poor correlations with subjective 
scores in this part of the study were important as they gave good rationale for the anti-
pruritic effect of this alternative medication as well as emphasizing the basis in 
objectiveness of different measures. 
However, the findings for S. Aureus of the trial indicated TCM might not be 
strong enough to suppress the acute inflammations caused by this AD-associated 
bacterium. Much work is still necessary to be done towards this aspect. 
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4.2.5 Safety of TCM use 
The approach of herb selection has to be very careful as adverse effects of 
Chinese herbal medicines have been reported (Perharic-Walton and Murray, 
1992;Ferguson et al., 1997;Fung et al., 1999). It is even more dangerous for practitioners 
to bear a misconception that TCM are "natural" substances and should not pose any side 
effects (Koo and Desai, 2003). Last but not least, the safety concern is heightened by the 
fact that standardisation of preparation, prescription and dosage of TCM is still very poor 
and varies with the prescriptions of individual practitioners, thus hindering its research 
progress. 
Based on safety emphasis, practitioners of TCM should be aware of the possible 
side effects with various TCM drugs and drug combinations that may occur, and greater 
caution should be exercised in their use (Koo and Desai, 2003). The Pentaherbs formula 
used in this trial might be too mild for Hong Kong AD patients to adapt for overcoming 
the local warm and moist climate, which are possible sources for AD worsening through 
the mechanism of alloknesis, thus only showing mild and gradual improvement 
throughout this part of the study. While the impact of such environmental factors vary 
among different regions, other herbs such as Cortex Moutan Radix, Radix Paeoniae alba, 
Potentilla chinensis ser and Radix glycyrrhizae were also commonly used in eczematous 
conditions (Zhang, 1990) and should be considered for trials of TCM in the long run. 
Earlier studies also noted that Clematis armamiii, Lophatherum graciie, Dictainnus 
dasycarpus, Tribidus terrestris and Schizonepeta temdfoUa had been shown to be 
beneficial and safe for the treatment of severe AD in both children (Sheehan and 
Atherton, 1994). 
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In Hong Kong, a controlled trial of Zemaphyte (a standardized formulation 
containing ten Chinese herbs) was conducted on 37 Chinese patients with recalcitrant AD 
for 8 weeks. No beneficial or adverse biochemical effects were demonstrated (Fung et al., 
1999). None of these herbs have pharmacological evidence regarding anti-allergic and 
anti-inflammatory effects. Clematis armandi used in Sheehan and Atherton's studies has 
diuretic effect and its long-term use necessitates potassium supplementation to avoid 
hypokalaemia. This herb was not used in our study in view of this safety concern. 
4.2.6 Summary 
To summarize, treatment with the Pentaherbs formula did not result in the 
hypothesized therapeutic effect, yet still remained useful as a supplementary medication 
in aiding acute inflammatory condition and sleeping, according to the findings. This 
study was limited by the relatively small sample size. Nevertheless, the clinical effects of 
the Pentaherbs capsules, and in particular, its usage in QoL improvement for AD, 
appeared to be impressive. TCM was appealing in aiding the patient to sleep better after a 
three-month intake, according to the Digitrac findings. The objectiveness of the device 
was further proved by its poor correlations with the scores from CDLQI, a subjectively-
based questionnaire to be filled in. However, the correlation of average activity with the 
total score might propose the role of Digitrac in assessing extent of QoL impairment in 
AD patients. In order to look for improvement of quality of life in depth, TCM trials in 
the future should consider using additional scoring scales, e.g. CDLQI, to aid related 
clinical investigations. 
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Baseline 6-week Follow-up 12-week Follow-
n=28 mean (SEM) mean (SEM) up mean (SEM) 
SCORAD 46.2 (3.4) 44.5 (7.5) 42.4 (3.7) 
objective SCORAD 36.1 (2.9) 35.1 (5.9) 33.3 (2.9) 
Extent 42.9 (3.9) 42.9 (7.3) 40.5 (3.8) 
Intensity 7.9 (0.6) 7.6 (1.3) 7.2 (0.7) 
Subjective Score 10.1 (0.8) 9.3 (1.6) 9.1 (1.0) 
Pruritus 5.43 (0.39) 5.17 (0.87) 5.17 (0.46) 
Sleep Loss 4.66* (0.45) 4.17* (0.70) 3 . 9 P (0.56) 
* Difference is significant at the 0.05 level (2-tailed). 
Table 4.7 Changes in the SCORAD and respective component scores of patients before 
and after traditional Chinese medication (TCM) clinical trial. 
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Pearson coefficient, p (n=28) 
CDLQI components Scratching Clothes Sleep Treatment Total 
CDLQI 
score 
Average wr i^ 0302 0 . 4 1 4 * 0 . 2 5 7 0.267 0 . 4 4 0 * ~ 
activity (g min"') 
Frequency-specific 0.257 0.266 0.196 0.147 0.291 
activity (mg min' ') 
Subjective score 0.491** 0.519** 0.535** 0.443* 0.573** 
Pruritus 0.468* 0.529** 0.467* 0.472* 0.580** 
Sleep loss 0.464* 0.462* 0.540** 0.377* 0.513** 
**/?< 0.01,*/? < 0 . 0 5 ; 2-tailed. “ 
Table 4.8 Correlations of Digitrac data with several components and the total Children's 
Dermatology Life Quality Index (CDLQI) score at the baseline of TCM trial. In 
particular, subjective scores reported by the parents correlated well with questions related 
to scratching and sleep loss and total CDLQI. Such a correlation could not be found using 
DiOgitrac data. 
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Figure 4.4 Visualization of wrist activities in early hours of sleep of a) a severe AD 
patient at the baseline of, b) the same patient at the end of TCM trial, and c) a normal 
healthy control of same age (6y) as reference. 
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a) 
Mean (SEM) First Second Third Average 
wrist activity (g min"') hour hour hour 0-3 hour 
B a s e l i n e i 2 K 2 f ^ 112.0 u J a 
(17.2) (16.0) (19.0) (12.2) 
End of 12-week trial 89.6 72.5 66.6 76.2 
(11.7) (10.1) (8.1) (8.1) 
p 0.055 0.043* 0.012* 0.001** 
** 尸< 0 .01 ,* / ?< 0.05 ;2-tailed. “ 
b) 
Mean (SEM) Total""“ 
Hz-specific wrist activity (mg min'') 0-1 Hz 0-2 Hz 0-3Hz 0-3 Hz 
B a s e l i n e 2 8 6 . 7 VTTS 
(36.9) (27.0) (21.9) (84.5) 
End of 12-week trial 157.5 140.6 112.1 410.3 
(20.9) (17.2) (13.9) (50.0) 
p 0.001** 0.003** 0.004** 0.002** 
< 0.01, 0.05 ； 2-tailecl. 
Table 4.9 Mean a) wrist activity for AD patients and controls (g min"') and b) frequency-
specific wrist activity (mg min"') before and after TCM trial. Difference among 2 groups 
was significant for every single hour over 0-3 hour except the first hour. 
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Average wrist activity First Second Third Average 
(g min'') hour of hour of hour of 0-3 
(n=56) sleep sleep sleep hours 
SCORAD Pearson p 0.100 0.369** 0.338* 0.358** 
p 0.462 0.005 0.011 0.007 
Objective Pearson p 0.095 0.388** 0.347** 0.368* 
SCORAD p 0.484 0.003 0.009 0.005 
Extent Pearson p 0.056 0.434** 0.396** 0.391** 
p 0.683 0.001 0.003 0.003 
Intensity Pearson p 0.107 0.363** 0.321* 0.350** 
p 0.434 0.006 0.016 0.008 
Erythema Pearson p 0.010 0.365** 0.292* 0.294* 
p 0.943 0.006 0.029 0.028 
Edema / Pearson p 0.060 .365** 0.343** 0.340* 
Papulation p 0.659 0.006 0.010 0.010 
Oozing/ Pearson p 0.290* 0.132 0.200 0.280* 
Crusting p 0.030 0.334 0.140 0.036 
Excoriation Pearson p 0.091 0.200 0.309* 0.269* 
p 0.504 0.140 0.020 0.045 
Lichenification Pearson p 0.040 0.248 0.239 0.233 
p 0.770 0.065 0.077 0.084 
Dryness Pearson p -0.010 0.334* 0.088 0.176 
p 0.942 0.012 0.520 0.194 
Subjective score Pearson p 0.096 0.234 0.243 0.254 
p 0.483 0.083 0.071 0.058 
Pruritus Pearson p 0.075 0.255 0.236 0.251 
p 0.583 0.058 0.080 0.062 
Sleep loss Pearson p 0.105 0.197 0.228 0.237 
p 0.440 0.147 0.091 0.079 
* * p < 0 . 0 ! , * ; ? < 0.05 ;2-tailed. ‘ 
Table 4.10 Correlations of average wrist activity (g min"') with SCORAD, objective 
SCORAD and related component scores using set of data from TCM trial. Objective 
wrist activity readings correlated well with objective clinical scores (SCORAD, objective 
SCORAD, extent and intensity), but not with subjective reports of pruritus and sleep loss. 
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Mean (SEM) " “ 
plasma level (pg ml' ') (,1=28) Baseline End of trial p 
0 013* 
(189) (101) ^ 
CTACK 1424 1087 
0 020* 
(136) (66) 
BDNF 1798 1378 
0 002** 
(177) (146) 
Substance-P 93.6 72.9 
(8.0) (6.4) 0.002** 
**/?< 0.01, 0 .05; 2-tailed. 
Table 4.11 Changes in laboratory markers before and after TCM clinical trial. 
n=56 BDNF SP 
I ^ r s o n p o T n 
Subjective Score ^ 0.061 0.407 
Pearson p 0.248 0.097 
Pruritus P 0.066 0.478 
Pearson p 0.235 0.117 
Sleep loss P 0.081 0.389 
Average wrist activity Pearson p 0.878** 0.897** 
(g min-i) 
p <0.00001 <0.00001 
Frequency-specific Pearson p 0.789** 0.801** 
activity (mg min ) 
p <0.00001 <0.00001 
**/?< 0.01 ； 2-tailed. “ 
Table 4.12 Correlations of pruritic markers, BDNF and substance P, with subjective 
symptom scores and Digitrac data. 
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4.3 Tacrolimus clinical trial 
Three boys and four girls, with a median (range) age of 11.8 (5.3-18.4) years, 
participated in the study. Their demographic characteristics are given in table 4.13. The 
average amount of Tacrolimus used over the 2-week course by the patients was 19.5 gm. 
One of the patients reported itch sensation with topical application of Tacrolimus. 
Compliance to treatment was good and there was no report of oral antihistamine or 
topical CS usage during the study period for all patients. 
Their median (interquartile range) objective SCORAD scores before and after 
treatment were 27.2 (24.8-36.7) and 23.9 (22.6-36.5), respectively —0.248). The overall 
SCORAD scores before and after treatment were 36.1 (32.8-45.7) and 29.4 (22.6-36.5), 
respectively (/7=0.059; Figure 4.5). The total SCORAD was reduced in six patients (range: 
8-36% reduction) and remained similar in 1 patient. No significant change in the area or 
intensity component of SCORAD was detected 14 days after treatment (p=0.48,p=0.115, 
respectively). The median (interquartile range) of pruritus and sleep disturbance 
component of the SCORAD reduced from 5.0 (5.0-6.5) and 4.0 (3.5-5.0) to 4.0 (2.0-5.0) 
and 3.0 (0.5-4.5); /7=0.033 for pruritus, p=0.268 for sleep, respectively, after performing 
paired-samples t-tests. The median scratching activity during the first 3 hours of sleep, as 
documented by the Digitrac movement recorder, reduced from 115.0 (64.8-215.5) g min'' 
at baseline (day 8)，to 67.6 (47.8-152.0) g min'' (p=0.052) on day 10, and 71.5 (51.0-
118.0) g mirfi (/?=0.028 by Wilcoxon signed rank test) at 2 weeks (day 22) (Figure 4.6). 
The daily symptom scores (n=6 pairs) reported each day separately by patients and 
parents for sleep disturbance agreed well with each other [intra class coefficient (ICC) 
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0.60-0.98]. These scores became significantly reduced two days following treatment 
(Figure 4.8; /7=0.03 and 0.013, respectively). Only six pairs of data were obtained for the 
daily scores because one young girl was unable to give reliable scores for her symptom of 
sleep disturbance. 
For laboratory findings, levels of TARC and CTACK (units in mean (SEM)) 
decreased significantly from 1135(462) to 514 (345) and from 1605 (283) to 1375(270) 
pg ml"', respectively (p=0.018) (Table 4.14). The levels of pruritic markers BDNF and SP, 
however, did not show any statistical significance. 
The small pilot study have successfully demonstrated that scratching movements, 
objectively measured with the Digitrac, and subjective score of itch and sleep disturbance 
can be separately recorded to assess therapeutic effects of a treatment. Tacrolimus 
appeared to have faster effects on subjective than objective symptomatology. The study 
also identified that battery life span (usually 14 days) is not a limiting factor for serial 
scratching measurement but the memory capacity of Digitrac (10-hour overnight 
recording) is. In order to monitor the serial effects of a tested medication, the data have to 
be downloaded daily. 
Due to the small sample size and the wide age range, specific comments as to why 
the extent and subjective symptoms are not improved were not able to be made. Although 
AD-associated chemokines showed a significantly reduced level, SCORAD, BDNF and 
SP did not. It might be that the change in disease extent and intensity as measured by the 
SCORAD and laboratory parameters were insensitive in a short test period of two weeks. 
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Measurement of subjective symptoms is notoriously unreliable, especially with the small 
sample size. The rapid onset of action for Tacrolimus described in this open-label study 
should be confirmed with a double-blind randomized controlled trial using our dual 
approach, combining objective and subjective tools. More importantly, we propose that 
all novel topical and systemic therapy should be evaluated with such a combined 
approach. Despite these, individual patients might significantly benefit from the use of 
this medication. Tacrolimus appeared to promptly improve sleep disturbance within days 
but did not reduce scratching at two weeks following its use. A large randomized 
placebo-control study is underway to evaluate the rate and extent of itch reduction of 
Tacrolimus in children with AD. 
Tacrolimus has played an important part in the treatment of paediatric AD since 
its introduction in 2001, yet the recently recommended black box warning from the U.S. 
Food and Drug Administration (FDA) has led to a re-examination of its role, particularly 
in paediatric patients (US Food and Drug Administration, 2005). What worried the 
scientists was the possible elevation of blood level for patients who received sustained 
medication of Tacrolimus, which might lead to adverse effects, if any, after prolonged 
application over large surfaces of skin (Berger et al, 2006). Increased rate of lymphoma 
was shown by dermal toxicity and carcinogenicity studies in animal models (Niwa et al., 
2003)，yet the doses far exceeded values achieved by topical use in humans. Therefore, as 
prolonged overuse of topical CS to certain anatomical areas including the face has a 
particular potential for adverse events like skin atrophy, striae, systemic absorption and 
adrenal suppression (Berger et al., 2006), second-line treatments of AD like Tacrolimus 
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are still of great necessity, yet should be used only if other therapies are ineffective or 
inappropriate and the course of application should be short-term and intermittent. 
Nevertheless, strict monitoring clinical dose of both medications is necessary. 
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Figure 4.5 Changes in total SCORAD scores during the 2-week study period of 7 patients 
in Tacrolimus pilot study. Treatment commenced on day 8 following a one week run-in 
and completed on day 21. 
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Figure 4.6 Average wrist activity (g min'^) for the first 3 hours of sleep of the patients 
during Tacrolimus treatment. 
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Figure 4.7 Frequency spectra of wrist activities in the early hours of sleep of (a) a severe 
AD patient at the baseline of, (b) the same patient at the end of Tacrolimus trial with (c) a 
normal subject of same age as reference. Most activities occur at 0 - 2 Hz. 
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Figure 4.8 Subjective daily scores of sleep disturbance by parents and patients in 
Tacrolimus clinical trial. 
Mean (SEM) 
plasma level (pg ml"') (n=7) Baseline End of trial P 
TARC rT35 5\A 
(462) (345) 0.018* 
CTACK 1605 1375 
(283) (270) 0.018* 
BDNF 1621 1502 
NS 
(206) (156) 
Substance-P 71.4 70.9 
NS 
(9.6) (9.6) ^^ 
* p < 0.05, 2-tailed. ； NS, not significant. 
Table 4.14 Changes in laboratory markers before and after Tacrolimus clinical trial. 
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4.4 Application of Digitrac in other areas of study 
4.4.1 Pemphigoid gestationis case study 
Pemphigoid gestationis (PG) is a rare, yet intensely pruritic bullous dermatologic 
disease of pregnancy and the postpartum period. It usually starts around the second or 
third trimester of pregnancy, with an estimated incidence of one in 50,000 pregnancies 
(Wong and Chua, 2002;mbros-Rudolph et al, 2006). The exact incidence among the 
Chinese is unknown. PG may be associated with Graves disease, hydatidiform moles and 
choriocarcinomas (Shornick, 1993;Chimanovitch et al., 1999). The patient in this case 
study had a history of chorioangioma in her first pregnancy and Graves disease in the 
second pregnancy and the history matched with such associations. 
In PG, chemoattraction of eosinophils and their subsequent degranulation is 
followed by the action of proteolytic enzymes, which dissolve the bond between 
epidermis and dermis. T-helper cells have been implicated in the very early stages of 
autoimmune response and may exercise a broad influence in subepidermal blister 
formation in this disease (Fabbri et al, 2003). 
The onset of PG is abrupt with intense pruritic urticarial lesions on the trunk, 
which usually spared the face, mucosal membranes, palms, and soles (Engineer et al., 
2000). Lesions begin usually on the abdomen adjacent to the umbilicus, though atypical 
presentations like palm and soles are observed. The clinical course is variable; many 
experience spontaneous resolution during the later part of gestation, but some of which 
may have flare again during the time of delivery. The patient in this case study had a 
transient recurrence in the immediate postpartum period. Recurrence in majority of 
patients during subsequent pregnancies has been reported, but there was no evidence that 
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the disease will be more severe in subsequent pregnancies. The patient must be monitored 
closely in subsequent pregnancies. 
Nocturnal itch pattern of the patient documented with the Digitrac wrist monitor 
showed intensive scratching movements (Figure 4.9a), with an average value of 181.0 士 
43.5 (mean 土 SEM) g min'' for the first three hours, which was higher than the average 
value of 113.4 土 10.2 g min'' for the group of 43 eczema subjects in validation study. 
Most wrist activities are slow movements at 0 to 2 Hz (Figure 4.10). The readings 
indicated the large extent of pruritus and nocturnal sleep disturbance of this patient. The 
wrist activities of a normal person and that of a patient with severe eczema were also 
shown as reference (Figure 4.9b and 4.9c). The frequency range of activity was in similar 
to the scratching activities at 0 to 3 Hz in eczema subjects. Basing on these results and 
comparisons of pruritus patterns of long-term AD patients, the intense scratching and 
discomfort experienced by patients with pemphigoid gestationis must not be 
underestimated. 
The patient was symptomatica!ly treated with antihistamines (chlorpheniramine 
meleate 5 mg) and topical CS (flucinolone acetonide 0.025%) and her skin symptoms 
resolved over a period of 2 weeks. She was also treated as having Graves disease with 
propylthiouracil (50 mg, twice daily) for two months. Subsequently, she gave birth at 
thirty-nine weeks three days of gestation by normal delivery to a healthy baby girl who 
weighed 2,50 kg with Apgar scores of 9 and 10 at one minute and five 5 minutes, 
respectively. She had recurrence of blistering lesions on her hands and trunk four days 
postpartum but the lesions subsided on further treatment with topical CS. 
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This short report served to alert clinicians, especially obstetricians and general 
practitioners, of the importance of considering the various differential diagnoses in a 
pregnant woman with bullous generalized itch. A dermatologist, an obstetrician and a 
paediatrician must coordinate care for patients with pemphigoid gestationis. Although PG 
is an uncommon disease in pregnancy among the Chinese, and differential diagnoses may 
include other bullous conditions, this diagnosis can be readily confirmed with 
histopathological studies. This case also illustrated that the scratching and discomfort 
experienced by patients with pemphigoid gestationis were intense and must not be 
underestimated. As itch is difficult to be documented objectively, the Digitrac monitor 
could help determine on its management, such as the choice of various sedating 
antihistamines or initiation of systemic CS if the itch is severe. Digitrac might also be 
helpful in monitoring its intensity and frequency before and following treatments. 
4.4.2 T-cell lymphoma case study 
Previous clinical trials stressed the wrist activities between 0 and 3 Hz for the first 
three hours of sleep as good indicator of eczema severity, nocturnal itch and sleep 
disturbance in children. It was also found that wrist activities in this patient occurred 
primarily in the first few hours of sleep at baseline before receiving chemotherapy 
(Figure 4.11). The intensity of these movements was even higher than that in patients 
with severe eczema, with an average value of 223.6 士 97.6 (mean 士 SEM) g min'' for the 
first three hours versus 113.4 士 10.2 g min"' for the group of 43 eczema subjects, while 
decreases to 69.2 士 9.9 g min"' at Day 6. The frequency pattern also showed a drastic 
decrease after chemotherapy, with a 4-year-old control as reference (Figure 4.12). 
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Interestingly, the itch was not relieved with antihistamines but by chemotherapeutic 
treatment of the underlying malignancy, implying the fact that mechanisms other than 
histamine may be involved in the pathophysiology of pruritus in this patient. Most wrist 
activities were very slow ones, with a strong emphasis at 0 to 1 Hz region only. The 
frequency bandwidth is lower than that of AD patients. 
It is a well-known paradigm in dermatology as well as in oncology that 
malignancies, among other differential diagnoses, must be considered in any patients with 
new onset of generalized itch (Kleyn et al” 2006). This consideration is especially 
important if the patient does not have any apparent rash to account for the symptom. The 
other differential diagnoses of generalized itch without a primary dermatological etiology 
includes iron deficiency anaemia, thyroid disease, hepatic failure, drugs, and 
polycythaemia rubra vera. Delayed or missed diagnosis in these conditions may not cause 
immediate mortality. Conversely, delays in diagnosing malignancy such as lymphoma 
may result in widespread dissemination and irreversibly loss of time for treatment. 
This second case study served to alert dermatologists, oncologists, paediatricians 
and general practitioners, of the importance of considering the various differential 
diagnoses in a previously well child with an unexplained generalized itch. This case also 
\ 
further challenged the anti-pruritic effect of antihistamines in this case, which the 
controversy is the same as for AD patients. The application of Digitrac illustrated further 
the potential possibilities of using the device in differential diagnosis as well as 
quantifying itch before and following treatment in various conditions associated with 
itching and scratching with different drugs, and in all patients with chronic pruritus, not 
only confined in AD. 
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Figure 4.9 Average wrist activities of (a) the woman with pemphigoid gestationis, (b) a 
21-year-old male with severe atopic dermatitis, and (c) a normal 21-year-old female as 
reference. 
94 
a) 
nrnqJlLl S^|>ecttaAt:l2!l1:»AK 
12:20 AM\ |4 a 2. 4. 8. 10. 
I； 10, Avtraqe Spectrum 
\ m • » 
0. 2. 4. 6. 8. 10. Frvqutncy 
b) 
12:30 oSk I 
vli (<;>( V 2. 4. & & ia 制 AMN^ W^ 
1Q Awraqc SpttctiMiii 
12:50 AmV i l 一 
0 , « A i i ^ : � 1 1 ^ 
01:10 A M N ^ I ^ H k , O c T T 4 6 8 10 
DiJOAir!^ ’ ’ _ - . 
0. 2. 4. 6. 8. 10. 
Frtquancy 
C) 
n r n g n ；pSp«ar»Al: 12:06:51 AM 
12:10 A八 
12=20 ^ 瓜 
\ Avtaat-SB柳um 
激 〜 I I ； 
W:40 AIlV. I ！ 
1?:50Air^  \ 2 «. 6. e 10. 
I11:00AM\ 
0. 2. 4. 6. B. 10. 
Frequency 
Figure 4.10 Frequency spectra in the early hours of sleep of (a) the patient suffering from 
pemphigoid gestationis, (b) a 21-year-old male with severe atopic dermatitis, and (c) a 
normal 21-year-old female as reference. Note that most activities occur at 0 - 2 Hz. 
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Figure 4.11 Average wrist activities of the patient suffering from T-cell lymphoma at 
(from up to down) (a) baseline, (b) on day 6 following chemotherapy, and (c) a normal 
subject as reference. 
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Figure 4.12 Wrist activities and frequency spectra in the early hours of sleep at (a) 
baseline, (b) on day 6 following chemotherapy, and (c) a normal subject as reference of 
the patient with lymphoma. Note that most activities occur at 0-1 Hz. 
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Chapter 5 
Further Discussions and Conclusion 
The research on pruritus management and development of a more effective and 
tailored regime is necessary, yet slow due to the complexity of neurophysiological and 
neuroimmunological complexity of itch pathophysiology (Paus et al., 2006a). In 
developing animal models of itch, direction has already been changing from acute 
injection ones to disease-related approaches. The difficulties in obtaining a methodology 
for objective, reproducible quantification of pruritus is also critical. While the majority of 
siinple pruritus researches still treat visual analogue scales as the gold standard, we aim to 
introduce Digitrac as an alternative for objective behavioral assessments. 
The whole picture of CNS and peripheral nervous system has been explored a lot 
in the past few years. Basing on the fact that sleep disorder is still one of the most 
tremendous problem, and that currently there are no accurate remedies to deal with, 
antihistamines will remain as a main basis, especially basing on their sedative effects. 
Yet it becomes more apparent and effective that a treatment regime basing on a targeting 
combination of both the peripheral production of inflammation-induced itch signals and 
the peripherally incited vicious cycles that perpetuate itch and cause spinal and central 
sensitization to itch will be the next generation of anti-pruritic treatment strategy. It is 
therefore foreseeable that combination of drugs that counteract chronic central itch 
sensitization with peripheral anti-inflammatory agents is a particularly sensible approach 
beyond the antihistamine horizon. 
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To conclude for the whole study, it has fulfilled its primary objective to look for 
alternatives in objective assessments of pruritus. It is hoped that measurement of wrist 
movements served the purpose as a better alternative for clinicians and researchers to 
quantify important clinical data on pruritus and sleep loss in an objective, home-based 
and convenient manner. 
To further apply the device in research, continuous measurements should be 
performed. In the validation part, only one single night was measured. Continuous 
measurements of wrist activities might throw more lights on any differences between 
monitoring over weekdays versus weekend, or examination versus usual school days, or 
school days versus long vacation. Moreover, usage of the device might not be confined 
in AD only, but also be applicable in other diseases with movement disorders, e.g. 
Parkinson's tremor. 
Concerning the use of the device in atopic dermatitis research, emphasis should be 
focused on the early hours of sleep at low frequency range. 1-2 days of recording appears 
to be sufficient for meaningful data capturing, though consecutive measurement would be 
suggested. Moreover, the device should be used alongside with other outcome measures, 
e.g. CDLQI in order to take a dual approach to consider both objective and subjective 
outcome measures simultaneously. 
For localized lesions of AD, usage of topical corticosteroids remains its key role 
to sooth the acute worsened situation. In fact, a short courses steroid with appropriate 
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potency is the cheapest, safest, and the most effective medication to apply for early stages 
of skin inflammation. However, one should never neglect the growing importance of 
alternatives including traditional herbal medication, in particular, Chinese herbs. 
Application of tacrolimus possesses no burning sensation. For an ethical scientist and 
practitioner, safety should always come first. Last but not least, AD skin lesions are often 
associated with secondary inflection of Staphylococcus aureus. Treatment of antibiotic is 
still necessary 
It is foreseeable that more and more new treatment formulae will be out soon. For 
the researchers, possible negative impacts of all these treatments have to be informed 
clearly to the patients and subjects. Last but not least, patience and care towards them is a 
must for all of the researchers in putting effort to work against the diseases that trouble 
millions for long. 
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中药對中阈藉濕该病童的療效及安全性 
H s a z 
濕疼是一種由致敏原弓丨起的常見皮膚炎病。濕疼和哮喘等敏感病爲查港兒童最常患上的 
慢性疾病之一 ’約九成濕疼病童的發病年齡在五歲以下。治療濕疼以潤膚及外敷薛爲 
主’近年來中韵開始受到重視’但其對濕疼之效果及副作用，卻未被深入研究。 
研究目的：中醫薛對中國藉濕疼病童的療效及安全性° 
是項研究將於門診部徼求中國籍濕渗病童。並根據_工作小組提出的SCORAD指數及 
其它濕疼指數’作臨床評定濕疼的程度。再者，中薛對身體的生理功能如肝、賢及血的 
影響，也會小心跟進。 
項硏究將包括臨床指標及實驗室指標。負責這硏究的敏感科醫生，會先爲貴子弟抽取約 
5毫升血液以化驗免疫球蛋白E的濃度，嗜伊紅細胞陽離子蛋白含量及其他發炎指標的 
濃度；而兒童皮膚科醫生則會詳細評估貴子弟濕疼的嚴重程度。貴子弟將會接受中薛共 
12週’如您或您的子女對當中成份產生敏感’請停止服用。請將現在或以往的醫療記 
錄及對那些物質有過敏的情況告訴醫生（或醫護人員）。通常中薛不會干擾您或您的子 
女所服用的其他藥物。但請將您所服食或準備服食的藥物（包括非經處方得到的藥物） 
告訴醫生。每日按醫生的處方服食’是否跟食物一起服用均可。爲了可以控制濕疼，持 
續依照醫生處方服用十分重要。如少服食一次’只要繼續依照正常服藥時間便可。任何 
藥物都可能導致一些非預定的反應或稱副作用。大部份病人都能接受本藥。副作用通常 
都屬輕微。如果出現不尋常徵狀或徵狀持續或惡化，請告知醫生。包裝盒及包裝上印有 
藥物有效日期’切勿使用過期藥物。放於室溫乾爽處。小心存放，避免被小童誤服。 
硏究人員亦會於期間給予貴子弟Digi_trac手部運動記錄器，並對解釋使用方法�Digitrac 
手部運動記錄器本身用於記錄運動員運動情況，並協助其改善表現；今次乃首次用於醫 
療方面，並在是次硏究中’記錄病童於入睡前的手部抓癢三維擺動幅度，以進行數據分 
析，客觀及無創地評估兒童在療程其間，其睡眠質素及痕癢狀況。 
同意書 
本人爲病人 之父母，現同意本人之子女參予這項硏究。本人明白並 
接受上述研究之要求，在有需要時也可向負責此硏究的醫生詢問子女各項測試的結果。 
本人也明白可以隨時退出此項硏究而不需作出任何解釋，而本人的子女將繼續享有和現 
時同樣質素的治療。病人資料只會用於此項硏究，不會公開。 
父/母姓名： 父/母簽署： 
父/母之身份証號碼： 簽署日期： 
見証人姓名： 見証人簽署： 
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以Digitrac渾動記錄器評估Tacrolimus (Protopic®)無頷固醇外敷藥 
對中國藉濕疼病童的痕痛及睡眠療效 
硏究背景 
濕疼是一種由致敏原引起的常見皮膚敏感病，爲香港兒童最常患上的慢性敏感疾病之一。很多 
患上濕疼的兒童到晚間會因爲痕癢，難以入睡’導致日間缺乏精神’或嚴重影響課堂及各類活 
動的表現；又因於睡前不斷抓癢、以致弄損皮膚，影響濕疼復原速度。治療濕疼以潤膚及外敷 
類固醇薛爲主’近年市場出現不含類固醇的藥膏，惟其成效及對免疫系統之影響仍有待仔細硏 
究。 
探討Tacrolimus(Protopi’c®)無類固醇外敷藥對中度至嚴重濕疼病童之療效及對免疫系統之影 
響’並同時使用Di'gkrac手部運動記錄器，無創地觀察及硏究中國藉濕疼病童在治療過程中睡眠 
質素及痕癢情況。 
是項硏究將維時約四星期。首先兒科醫生及研究人員會於門診部徵求虫厘籍濕疼病童，並根據 
M工作小組提出的SCORAD指數及其它濕疼指數，作爲臨床評定濕疼的程度，並仔細解釋整個 
硏究流程。 
兒科醫生會於期間將藥物給予家長，並詳細解釋其藥性，潛在副作用，使用方法及劑量。若有 
任何不良反應，醫生會即時停止藥物臨床測試。由於藥物並不納入在醫管局標準藥物名冊內， 
病人如有興趣於測試後繼續使用藥物，則需出示醫生紙自行購買。 
研究人員亦會於期間給予貴子弟Digitrac手部運動記錄器，並對解釋使用方法。Dig丨trac手部運 
動記錄器本身用於記錄運動員運動情況，並協助其改善表現；今次乃首次用於醫療方面，並在 
是次硏究中，記錄病童於入睡前的手部抓癢三維擺動幅度，以進行數據分析，客觀及無創地評 
估兒童在療程其間，其睡眠質素及痕癢狀況。 
是項硏究將包括臨床及贲驗室指標。貴子弟將會定期在門診隨訪，期間亦會配合及進行其他臨 
床及血液檢驗，以仔細評估病情及治療效果。家長及病童亦會獲發一張睡眠狀況日記，作記錄 
小朋友每晚之睡眠狀況，以跟進藥物療效。 
有關病人的個人資料及硏究數據，除相關之硏究人員外，將嚴守秘密，以保障個人私隱。 
亂意書 
本人爲病> 之父母，現同意本人之子女參予這項硏究。本人明白並接受上述 
硏究之要求，在有需要時也可向負責此硏究的醫生詢問子女各項測試的結果。本人也明白可以 
隨時退出此項硏究而不需作出任何解釋’而本人的子女將繼續享有和現時同樣質素的治療。 
父/母姓名： 父/母簽署： 
父/母之身份証號碼： 簽署日期： 
見証人姓名： 見証人簽署： 
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